| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.851 | 0.002 | 0.851 | Anesthetic local | 0.464 0.005 DBMET03083 0.254 0.019 DBMET01429 | ||
| 0.738 | 0.006 | 0.933 | Aldehyde oxidase inhibitor | 0.933 0.003 DBMET03083 0.726 0.006 DBMET01429 | DBMET03083 | |
| 0.687 | 0.004 | 0.687 | Anesthetic general | 0.632 0.004 DBMET03083 0.492 0.008 DBMET01429 | ||
| 0.683 | 0.007 | 0.683 | Spasmolytic | 0.657 0.008 DBMET03083 0.232 0.099 DBMET01429 | ||
| 0.649 | 0.004 | 0.649 | Sigma receptor agonist | 0.615 0.004 DBMET03083 0.462 0.014 DBMET01429 | ||
| 0.624 | 0.013 | 0.661 | Vasodilator, peripheral | 0.661 0.009 DBMET03083 0.363 0.069 DBMET01429 | DBMET03083 | |
| 0.598 | 0.004 | 0.64 | Peroxidase inhibitor | 0.583 0.005 DBMET03083 0.64 0.004 DBMET01429 | DBMET01429 | |
| 0.577 | 0.009 | 0.583 | Vasodilator, coronary | 0.583 0.008 DBMET03083 0.32 0.072 DBMET01429 | DBMET03083 | |
| 0.552 | 0.014 | 0.565 | GABA C receptor rho-3 antagonist | 0.489 0.029 DBMET03083 0.565 0.012 DBMET01429 | DBMET01429 | |
| 0.525 | 0.019 | 0.529 | Calcium channel L-type activator | 0.248 0.207 DBMET03083 0.529 0.018 DBMET01429 | DBMET01429 | |
| 0.526 | 0.021 | 0.612 | Histamine release inhibitor | 0.508 0.026 DBMET03083 0.612 0.009 DBMET01429 | DBMET01429 | |
| 0.508 | 0.004 | 0.508 | Lipocortins synthesis antagonist | 0.438 0.006 DBMET03083 0.447 0.005 DBMET01429 | ||
| 0.508 | 0.005 | 0.508 | Calcium channel activator | 0.433 0.015 DBMET03083 0.384 0.031 DBMET01429 | ||
| 0.497 | 0.015 | 0.706 | Cardiotonic | 0.706 0.005 DBMET03083 | DBMET03083 | |
| 0.454 | 0.01 | 0.478 | Cyclic AMP phosphodiesterase inhibitor | 0.478 0.008 DBMET03083 0.314 0.036 DBMET01429 | DBMET03083 | |
| 0.448 | 0.016 | 0.462 | Psychostimulant | 0.462 0.015 DBMET03083 0.229 0.067 DBMET01429 | DBMET03083 | |
| 0.434 | 0.021 | 0.66 | Superoxide dismutase inhibitor | 0.66 0.005 DBMET03083 0.625 0.006 DBMET01429 | DBMET03083 | |
| 0.412 | 0.004 | 0.412 | Cyclooxygenase 3 inhibitor | 0.237 0.01 DBMET03083 0.235 0.01 DBMET01429 | ||
| 0.407 | 0.022 | 0.514 | Vasodilator | 0.514 0.011 DBMET03083 | DBMET03083 | |
| 0.381 | 0.022 | 0.48 | Interleukin agonist | 0.336 0.033 DBMET03083 0.48 0.01 DBMET01429 | DBMET01429 | |
| 0.348 | 0.005 | 0.377 | Adenylate kinase inhibitor | 0.337 0.005 DBMET03083 0.377 0.004 DBMET01429 | DBMET01429 | |
| 0.368 | 0.026 | 0.368 | Anticonvulsant | 0.238 0.062 DBMET03083 0.192 0.088 DBMET01429 | ||
| 0.345 | 0.01 | 0.345 | Nav1.2 sodium channel blocker | 0.277 0.018 DBMET03083 | ||
| 0.34 | 0.006 | 0.34 | Nav1.3 sodium channel blocker | 0.298 0.009 DBMET03083 | ||
| 0.388 | 0.066 | 0.388 | Transcription factor NF kappa B inhibitor | 0.334 0.082 DBMET03083 0.384 0.067 DBMET01429 | ||
| 0.397 | 0.08 | 0.608 | 5 Hydroxytryptamine release inhibitor | 0.581 0.014 DBMET03083 0.608 0.01 DBMET01429 | DBMET01429 | |
| 0.33 | 0.016 | 0.383 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.367 0.01 DBMET03083 0.383 0.009 DBMET01429 | DBMET01429 | |
| 0.306 | 0.013 | 0.306 | Acetylcholine M1 receptor antagonist | 0.273 0.02 DBMET03083 0.137 0.088 DBMET01429 | ||
| 0.316 | 0.026 | 0.508 | Tyrosine 3 hydroxylase inhibitor | 0.508 0.004 DBMET03083 0.331 0.021 DBMET01429 | DBMET03083 | |
| 0.35 | 0.064 | 0.589 | Cholesterol antagonist | 0.51 0.031 DBMET03083 0.589 0.02 DBMET01429 | DBMET01429 | |
| 0.287 | 0.006 | 0.287 | Nav1.6 sodium channel blocker | 0.251 0.009 DBMET03083 0.122 0.092 DBMET01429 | ||
| 0.294 | 0.015 | 0.294 | Interleukin 6 antagonist | 0.294 0.016 DBMET03083 0.215 0.033 DBMET01429 | ||
| 0.309 | 0.031 | 0.309 | ErbB-1 antagonist | 0.292 0.035 DBMET03083 0.204 0.084 DBMET01429 | ||
| 0.366 | 0.09 | 0.366 | 15-Lipoxygenase inhibitor | 0.207 0.206 DBMET03083 0.36 0.094 DBMET01429 | ||
| 0.319 | 0.048 | 0.356 | Insulysin inhibitor | 0.316 0.049 DBMET03083 0.356 0.032 DBMET01429 | DBMET01429 | |
| 0.275 | 0.01 | 0.551 | Carbonic anhydrase XV inhibitor | 0.131 0.039 DBMET03083 0.551 0.003 DBMET01429 | DBMET01429 | |
| 0.257 | 0.008 | 0.257 | Calcium antagonist | 0.242 0.009 DBMET03083 | ||
| 0.258 | 0.01 | 0.26 | GABA C receptor rho-2 antagonist | 0.231 0.016 DBMET03083 0.26 0.01 DBMET01429 | DBMET01429 | |
| 0.271 | 0.023 | 0.326 | Amylase inhibitor | 0.326 0.015 DBMET03083 0.296 0.019 DBMET01429 | DBMET03083 | |
| 0.301 | 0.057 | 0.304 | DNA damaging | 0.304 0.055 DBMET03083 0.235 0.09 DBMET01429 | DBMET03083 | |
| 0.257 | 0.016 | 0.257 | Calcium channel blocker | 0.144 0.064 DBMET03083 | ||
| 0.277 | 0.035 | 0.317 | DNA methyltransferase I inhibitor | 0.291 0.029 DBMET03083 0.317 0.021 DBMET01429 | DBMET01429 | |
| 0.275 | 0.034 | 0.275 | Neuropeptide Y2 antagonist | 0.264 0.044 DBMET03083 0.227 0.081 DBMET01429 | ||
| 0.248 | 0.008 | 0.462 | NADH dehydrogenase inhibitor | 0.442 0.004 DBMET03083 0.462 0.004 DBMET01429 | DBMET01429 | |
| 0.369 | 0.131 | 0.786 | Caspase 9 stimulant | 0.786 0.013 DBMET03083 0.313 0.18 DBMET01429 | DBMET03083 | |
| 0.247 | 0.011 | 0.272 | Catenin beta inhibitor | 0.198 0.034 DBMET03083 0.272 0.008 DBMET01429 | DBMET01429 | |
| 0.246 | 0.012 | 0.314 | Nav1.1 sodium channel blocker | 0.314 0.007 DBMET03083 | DBMET03083 | |
| 0.237 | 0.005 | 0.328 | Electrolyte absorption antagonist | 0.269 0.004 DBMET03083 0.328 0.004 DBMET01429 | DBMET01429 | |
| 0.275 | 0.044 | 0.335 | MAP kinase kinase 2 inhibitor | 0.335 0.024 DBMET03083 0.286 0.04 DBMET01429 | DBMET03083 | |
| 0.25 | 0.023 | 0.75 | Alpha-N-acetylglucosaminidase inhibitor | 0.674 0.003 DBMET03083 0.75 0.003 DBMET01429 | DBMET01429 | |
| 0.277 | 0.051 | 0.317 | Gastrin inhibitor | 0.301 0.032 DBMET03083 0.317 0.023 DBMET01429 | DBMET01429 | |
| 0.228 | 0.005 | 0.299 | Interferon agonist | 0.299 0.003 DBMET03083 0.12 0.017 DBMET01429 | DBMET03083 | |
| 0.299 | 0.079 | 0.37 | Immunostimulant | 0.37 0.059 DBMET03083 0.293 0.08 DBMET01429 | DBMET03083 | |
| 0.295 | 0.077 | 0.441 | Interleukin 2 agonist | 0.263 0.105 DBMET03083 0.441 0.017 DBMET01429 | DBMET01429 | |
| 0.225 | 0.009 | 0.635 | Porphobilinogen synthase inhibitor | 0.506 0.003 DBMET03083 0.635 0.003 DBMET01429 | DBMET01429 | |
| 0.251 | 0.048 | 0.301 | DNA methylase inhibitor | 0.277 0.035 DBMET03083 0.301 0.027 DBMET01429 | DBMET01429 | |
| 0.196 | 0.006 | 0.196 | Toll-Like receptor 3 antagonist | 0.154 0.013 DBMET01429 | ||
| 0.26 | 0.072 | 0.454 | 5 Hydroxytryptamine uptake stimulant | 0.353 0.025 DBMET03083 0.454 0.007 DBMET01429 | DBMET01429 | |
| 0.233 | 0.047 | 0.301 | I kappa B kinase epsilon inhibitor | 0.196 0.074 DBMET03083 0.301 0.015 DBMET01429 | DBMET01429 | |
| 0.247 | 0.062 | 0.247 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.178 0.11 DBMET03083 | ||
| 0.19 | 0.006 | 0.19 | Histamine N-methyltransferase inhibitor | 0.168 0.009 DBMET03083 0.152 0.013 DBMET01429 | ||
| 0.212 | 0.03 | 0.212 | Acetylcholinesterase inhibitor | 0.187 0.037 DBMET03083 | ||
| 0.211 | 0.029 | 0.215 | Cholinergic antagonist | 0.215 0.028 DBMET03083 | DBMET03083 | |
| 0.207 | 0.026 | 0.373 | Aldehyde dehydrogenase inhibitor | 0.373 0.006 DBMET03083 0.3 0.012 DBMET01429 | DBMET03083 | |
| 0.282 | 0.101 | 0.4 | Antithrombotic | 0.4 0.049 DBMET03083 0.328 0.073 DBMET01429 | DBMET03083 | |
| 0.205 | 0.025 | 0.316 | Alkylator | 0.316 0.012 DBMET03083 0.163 0.04 DBMET01429 | DBMET03083 | |
| 0.201 | 0.024 | 0.216 | Acetylcholine muscarinic antagonist | 0.216 0.02 DBMET03083 | DBMET03083 | |
| 0.185 | 0.011 | 0.315 | GABA C receptor rho-1 antagonist | 0.184 0.011 DBMET03083 0.315 0.003 DBMET01429 | DBMET01429 | |
| 0.201 | 0.03 | 0.202 | Acetylcholine antagonist | 0.202 0.03 DBMET03083 | DBMET03083 | |
| 0.183 | 0.017 | 0.342 | GABA C receptor antagonist | 0.222 0.009 DBMET03083 0.342 0.004 DBMET01429 | DBMET01429 | |
| 0.211 | 0.046 | 0.272 | 5 Hydroxytryptamine 3E antagonist | 0.272 0.009 DBMET03083 0.177 0.113 DBMET01429 | DBMET03083 | |
| 0.18 | 0.015 | 0.18 | Acetylcholine nicotinic antagonist | 0.148 0.021 DBMET03083 | ||
| 0.209 | 0.044 | 0.229 | Cytidine deaminase inhibitor | 0.229 0.035 DBMET03083 0.189 0.053 DBMET01429 | DBMET03083 | |
| 0.212 | 0.05 | 0.301 | Amyloid beta precursor protein antagonist | 0.301 0.017 DBMET01429 | DBMET01429 | |
| 0.217 | 0.059 | 0.284 | Non-steroidal antiinflammatory agent | 0.159 0.105 DBMET03083 0.284 0.032 DBMET01429 | DBMET01429 | |
| 0.235 | 0.078 | 0.426 | DNA synthesis inhibitor | 0.352 0.03 DBMET03083 0.426 0.019 DBMET01429 | DBMET01429 | |
| 0.214 | 0.059 | 0.214 | Focal adhesion kinase 2 inhibitor | 0.154 0.124 DBMET03083 0.194 0.074 DBMET01429 | ||
| 0.162 | 0.008 | 0.197 | Glutamate release inhibitor | 0.124 0.019 DBMET03083 0.197 0.005 DBMET01429 | DBMET01429 | |
| 0.163 | 0.01 | 0.163 | Acetylcholine release stimulant | 0.162 0.011 DBMET03083 0.126 0.039 DBMET01429 | ||
| 0.198 | 0.045 | 0.479 | Phospholipase C inhibitor | 0.237 0.028 DBMET03083 0.479 0.007 DBMET01429 | DBMET01429 | |
| 0.18 | 0.028 | 0.456 | Chelator | 0.456 0.005 DBMET03083 0.118 0.055 DBMET01429 | DBMET03083 | |
| 0.192 | 0.05 | 0.192 | Cholinergic | 0.182 0.055 DBMET03083 | ||
| 0.17 | 0.03 | 0.241 | Aminopeptidase B inhibitor | 0.228 0.016 DBMET03083 0.241 0.014 DBMET01429 | DBMET01429 | |
| 0.181 | 0.041 | 0.235 | Hemostatic | 0.213 0.028 DBMET03083 0.235 0.024 DBMET01429 | DBMET01429 | |
| 0.181 | 0.042 | 0.181 | Interleukin 1 antagonist | 0.112 0.102 DBMET03083 0.15 0.057 DBMET01429 | ||
| 0.146 | 0.01 | 0.146 | Calcium channel L-type blocker | 0.11 0.02 DBMET03083 | ||
| 0.148 | 0.012 | 0.38 | Phenylalanine 4-hydroxylase inhibitor | 0.38 0.003 DBMET03083 0.343 0.004 DBMET01429 | DBMET03083 | |
| 0.186 | 0.051 | 0.265 | ATPase inhibitor | 0.265 0.01 DBMET03083 0.167 0.075 DBMET01429 | DBMET03083 | |
| 0.256 | 0.123 | 0.259 | Prostaglandin dehydrogenase inhibitor | 0.259 0.122 DBMET01429 | DBMET01429 | |
| 0.178 | 0.045 | 0.178 | Cytokine production inhibitor | 0.149 0.063 DBMET03083 | ||
| 0.19 | 0.057 | 0.434 | Succinate dehydrogenase inhibitor | 0.315 0.009 DBMET03083 0.434 0.004 DBMET01429 | DBMET01429 | |
| 0.155 | 0.023 | 0.242 | Sphingomyelinase inhibitor | 0.242 0.005 DBMET03083 | DBMET03083 | |
| 0.174 | 0.041 | 0.174 | Toll-Like receptor antagonist | 0.145 0.059 DBMET03083 | ||
| 0.218 | 0.088 | 0.261 | Antiamyloidogenic | 0.212 0.091 DBMET03083 0.261 0.066 DBMET01429 | DBMET01429 | |
| 0.159 | 0.029 | 0.159 | Calcium channel (voltage-sensitive) blocker | 0.102 0.081 DBMET03083 | ||
| 0.189 | 0.061 | 0.189 | Tumour necrosis factor antagonist | 0.146 0.105 DBMET03083 0.179 0.068 DBMET01429 | ||
| 0.132 | 0.005 | 0.196 | Interferon inducer | 0.196 0.004 DBMET03083 0.091 0.017 DBMET01429 | DBMET03083 | |
| 0.211 | 0.085 | 0.362 | Peptidyltransferase inhibitor | 0.362 0.01 DBMET03083 0.217 0.079 DBMET01429 | DBMET03083 | |
| 0.13 | 0.004 | 0.164 | Squalene epoxidase inhibitor | 0.164 0.003 DBMET03083 | DBMET03083 | |
| 0.202 | 0.077 | 0.275 | Amyloid beta aggregation inhibitor | 0.275 0.05 DBMET03083 | DBMET03083 | |
| 0.179 | 0.055 | 0.221 | Arachidonic acid antagonist | 0.221 0.016 DBMET03083 0.214 0.021 DBMET01429 | DBMET03083 | |
| 0.153 | 0.029 | 0.153 | TRPA1 agonist | 0.151 0.03 DBMET03083 0.147 0.033 DBMET01429 | ||
| 0.134 | 0.009 | 0.143 | Granulocyte macrophage colony stimulating factor agonist | 0.11 0.024 DBMET03083 0.143 0.006 DBMET01429 | DBMET01429 | |
| 0.21 | 0.086 | 0.352 | RNA-directed DNA polymerase inhibitor | 0.256 0.046 DBMET03083 0.352 0.024 DBMET01429 | DBMET01429 | |
| 0.226 | 0.102 | 0.226 | 5 Hydroxytryptamine 1E antagonist | 0.222 0.106 DBMET03083 0.193 0.139 DBMET01429 | ||
| 0.162 | 0.038 | 0.234 | Cathepsin H inhibitor | 0.138 0.056 DBMET03083 0.234 0.015 DBMET01429 | DBMET01429 | |
| 0.133 | 0.011 | 0.235 | Acyl-CoA dehydrogenase inhibitor | 0.215 0.004 DBMET03083 0.235 0.004 DBMET01429 | DBMET01429 | |
| 0.156 | 0.035 | 0.554 | Ferrochelatase inhibitor | 0.277 0.01 DBMET03083 0.554 0.002 DBMET01429 | DBMET01429 | |
| 0.173 | 0.058 | 0.24 | Phospholipase A2 inhibitor | 0.191 0.048 DBMET03083 0.24 0.026 DBMET01429 | DBMET01429 | |
| 0.148 | 0.035 | 0.183 | Interleukin 8 antagonist | 0.171 0.023 DBMET03083 0.183 0.018 DBMET01429 | DBMET01429 | |
| 0.137 | 0.025 | 0.15 | Anabolic | 0.15 0.018 DBMET03083 0.148 0.019 DBMET01429 | DBMET03083 | |
| 0.131 | 0.019 | 0.164 | Ornithine decarboxylase inhibitor | 0.122 0.024 DBMET03083 0.164 0.008 DBMET01429 | DBMET01429 | |
| 0.256 | 0.146 | 0.263 | Calpain 2 inhibitor | 0.263 0.14 DBMET03083 0.201 0.186 DBMET01429 | DBMET03083 | |
| 0.136 | 0.029 | 0.152 | Nitric-oxide synthase inhibitor | 0.152 0.021 DBMET03083 0.111 0.045 DBMET01429 | DBMET03083 | |
| 0.151 | 0.044 | 0.219 | Adenylate cyclase inhibitor | 0.205 0.025 DBMET03083 0.219 0.023 DBMET01429 | DBMET01429 | |
| 0.121 | 0.015 | 0.626 | GABA aminotransferase inhibitor | 0.084 0.042 DBMET03083 0.626 0.002 DBMET01429 | DBMET01429 | |
| 0.308 | 0.202 | 0.523 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.417 0.086 DBMET03083 0.523 0.024 DBMET01429 | DBMET01429 | |
| 0.134 | 0.034 | 0.321 | Potassium channel (Ca-activated) activator | 0.136 0.033 DBMET03083 0.321 0.005 DBMET01429 | DBMET01429 | |
| 0.148 | 0.048 | 0.201 | Ca2+-transporting ATPase inhibitor | 0.181 0.007 DBMET03083 0.201 0.003 DBMET01429 | DBMET01429 | |
| 0.104 | 0.006 | 0.104 | 5 Hydroxytryptamine 4 antagonist | 0.049 0.04 DBMET03083 0.049 0.041 DBMET01429 | ||
| 0.138 | 0.039 | 0.138 | Butyrylcholinesterase inhibitor | 0.134 0.04 DBMET03083 | ||
| 0.15 | 0.052 | 0.191 | Toll-Like receptor 2 antagonist | 0.191 0.028 DBMET03083 0.155 0.049 DBMET01429 | DBMET03083 | |
| 0.102 | 0.005 | 0.205 | Dihydropteroate synthase inhibitor | 0.038 0.029 DBMET03083 0.205 0.002 DBMET01429 | DBMET01429 | |
| 0.155 | 0.06 | 0.269 | Mannose-6-phosphate isomerase inhibitor | 0.215 0.023 DBMET03083 0.269 0.009 DBMET01429 | DBMET01429 | |
| 0.177 | 0.082 | 0.221 | P-glycoprotein inhibitor | 0.221 0.053 DBMET03083 | DBMET03083 | |
| 0.135 | 0.041 | 0.706 | GABA C receptor agonist | 0.321 0.008 DBMET03083 0.706 0.002 DBMET01429 | DBMET01429 | |
| 0.154 | 0.06 | 0.154 | Neuropeptide Y1 antagonist | 0.122 0.118 DBMET03083 0.153 0.06 DBMET01429 | ||
| 0.158 | 0.066 | 0.176 | Heat shock protein 90 antagonist | 0.176 0.051 DBMET03083 0.141 0.084 DBMET01429 | DBMET03083 | |
| 0.108 | 0.017 | 0.167 | Estrogen-related receptor beta agonist | 0.167 0.003 DBMET03083 0.107 0.018 DBMET01429 | DBMET03083 | |
| 0.146 | 0.055 | 0.188 | Heat shock protein 70 antagonist | 0.15 0.044 DBMET03083 0.188 0.009 DBMET01429 | DBMET01429 | |
| 0.097 | 0.007 | 0.196 | Alpha-mannosidase inhibitor | 0.196 0.003 DBMET03083 0.075 0.013 DBMET01429 | DBMET03083 | |
| 0.098 | 0.007 | 0.1 | Epithelial sodium channel blocker | 0.1 0.007 DBMET03083 0.078 0.013 DBMET01429 | DBMET03083 | |
| 0.159 | 0.07 | 0.251 | Diuretic | 0.176 0.056 DBMET03083 0.251 0.03 DBMET01429 | DBMET01429 | |
| 0.127 | 0.038 | 0.195 | Gastric antisecretory | 0.195 0.013 DBMET03083 | DBMET03083 | |
| 0.169 | 0.081 | 0.225 | LIM domain kinase 1 inhibitor | 0.142 0.106 DBMET03083 0.225 0.051 DBMET01429 | DBMET01429 | |
| 0.127 | 0.039 | 0.402 | UDP-glucose 4-epimerase inhibitor | 0.312 0.01 DBMET03083 0.402 0.005 DBMET01429 | DBMET01429 | |
| 0.15 | 0.063 | 0.15 | Toll-Like receptor 9 antagonist | 0.148 0.064 DBMET03083 | ||
| 0.268 | 0.181 | 0.305 | DNA directed DNA polymerase inhibitor | 0.305 0.159 DBMET01429 | DBMET01429 | |
| 0.15 | 0.064 | 0.21 | Adenylate cyclase stimulant | 0.21 0.01 DBMET03083 0.185 0.022 DBMET01429 | DBMET03083 | |
| 0.105 | 0.02 | 0.106 | Acetylcholine M2 receptor antagonist | 0.106 0.02 DBMET03083 | DBMET03083 | |
| 0.116 | 0.031 | 0.382 | Carbonic anhydrase VI inhibitor | 0.105 0.036 DBMET03083 0.382 0.004 DBMET01429 | DBMET01429 | |
| 0.202 | 0.118 | 0.268 | MAP kinase kinase 3 inhibitor | 0.268 0.018 DBMET01429 | DBMET01429 | |
| 0.101 | 0.018 | 0.41 | Biliverdin reductase inhibitor | 0.139 0.011 DBMET03083 0.41 0.002 DBMET01429 | DBMET01429 | |
| 0.093 | 0.012 | 0.12 | Gonadotropin-releasing hormone receptor agonist | 0.12 0.006 DBMET03083 0.056 0.05 DBMET01429 | DBMET03083 | |
| 0.106 | 0.025 | 0.246 | Aminopeptidase I inhibitor | 0.246 0.004 DBMET03083 0.173 0.009 DBMET01429 | DBMET03083 | |
| 0.124 | 0.044 | 0.162 | Mediator release inhibitor | 0.106 0.063 DBMET03083 0.162 0.024 DBMET01429 | DBMET01429 | |
| 0.121 | 0.042 | 0.121 | Toll-Like receptor 4 antagonist | 0.109 0.057 DBMET01429 | ||
| 0.104 | 0.025 | 0.104 | Acetylcholine M4 receptor antagonist | 0.101 0.028 DBMET03083 | ||
| 0.092 | 0.014 | 0.189 | Glutamate (mGluR6) antagonist | 0.09 0.016 DBMET03083 0.189 0.003 DBMET01429 | DBMET01429 | |
| 0.106 | 0.028 | 0.422 | Glutamate dehydrogenase inhibitor | 0.176 0.012 DBMET03083 0.422 0.004 DBMET01429 | DBMET01429 | |
| 0.085 | 0.008 | 0.167 | Mannosidase inhibitor | 0.167 0.004 DBMET03083 0.081 0.008 DBMET01429 | DBMET03083 | |
| 0.112 | 0.035 | 0.238 | Catalase inhibitor | 0.238 0.01 DBMET03083 0.213 0.013 DBMET01429 | DBMET03083 | |
| 0.11 | 0.033 | 0.18 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.12 0.029 DBMET03083 0.18 0.012 DBMET01429 | DBMET01429 | |
| 0.091 | 0.014 | 0.144 | Heat shock protein 90 beta antagonist | 0.144 0.005 DBMET03083 0.067 0.031 DBMET01429 | DBMET03083 | |
| 0.11 | 0.033 | 0.32 | Carbonic anhydrase XIII inhibitor | 0.089 0.044 DBMET03083 0.32 0.005 DBMET01429 | DBMET01429 | |
| 0.106 | 0.029 | 0.106 | Histamine H2 receptor antagonist | 0.104 0.031 DBMET03083 0.09 0.047 DBMET01429 | ||
| 0.262 | 0.185 | 0.289 | DNA polymerase beta inhibitor | 0.289 0.171 DBMET01429 | DBMET01429 | |
| 0.118 | 0.043 | 0.342 | Creatine kinase inhibitor | 0.342 0.004 DBMET03083 0.29 0.004 DBMET01429 | DBMET03083 | |
| 0.083 | 0.008 | 0.083 | Sodium/calcium exchanger inhibitor | 0.072 0.011 DBMET03083 0.059 0.021 DBMET01429 | ||
| 0.112 | 0.037 | 0.445 | Triose-phosphate isomerase inhibitor | 0.283 0.005 DBMET03083 0.445 0.003 DBMET01429 | DBMET01429 | |
| 0.184 | 0.11 | 0.41 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.175 0.117 DBMET03083 0.41 0.036 DBMET01429 | DBMET01429 | |
| 0.112 | 0.039 | 0.132 | Lanosterol 14 alpha demethylase inhibitor | 0.124 0.027 DBMET03083 0.132 0.02 DBMET01429 | DBMET01429 | |
| 0.124 | 0.053 | 0.124 | GABA receptor agonist | 0.104 0.072 DBMET03083 | ||
| 0.128 | 0.058 | 0.278 | Cholesterol synthesis inhibitor | 0.278 0.014 DBMET03083 0.138 0.051 DBMET01429 | DBMET03083 | |
| 0.112 | 0.043 | 0.162 | MAP kinase kinase 1 inhibitor | 0.162 0.012 DBMET03083 0.158 0.014 DBMET01429 | DBMET03083 | |
| 0.099 | 0.031 | 0.25 | Keratolytic | 0.142 0.016 DBMET03083 0.25 0.005 DBMET01429 | DBMET01429 | |
| 0.091 | 0.023 | 0.266 | NMDA receptor agonist | 0.117 0.014 DBMET03083 0.266 0.004 DBMET01429 | DBMET01429 | |
| 0.185 | 0.117 | 0.258 | Nitric-oxide synthase stimulant | 0.245 0.036 DBMET03083 0.258 0.027 DBMET01429 | DBMET01429 | |
| 0.134 | 0.067 | 0.248 | NADPH oxidase inhibitor | 0.125 0.076 DBMET03083 0.248 0.021 DBMET01429 | DBMET01429 | |
| 0.232 | 0.166 | 0.232 | Beta lactamase inhibitor | |||
| 0.088 | 0.021 | 0.868 | Alcohol oxidase inhibitor | 0.706 0.003 DBMET03083 0.868 0.002 DBMET01429 | DBMET01429 | |
| 0.122 | 0.056 | 0.122 | Alpha 2b adrenoreceptor antagonist | 0.105 0.07 DBMET03083 | ||
| 0.089 | 0.023 | 0.109 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.089 0.023 DBMET03083 0.109 0.009 DBMET01429 | DBMET01429 | |
| 0.189 | 0.124 | 0.22 | Calpain inhibitor | 0.22 0.094 DBMET03083 | DBMET03083 | |
| 0.088 | 0.023 | 0.185 | NMDA receptor glycine site agonist | 0.096 0.018 DBMET03083 0.185 0.003 DBMET01429 | DBMET01429 | |
| 0.108 | 0.044 | 0.325 | Alcohol dehydrogenase inhibitor | 0.178 0.015 DBMET03083 0.325 0.005 DBMET01429 | DBMET01429 | |
| 0.167 | 0.105 | 0.168 | Interleukin antagonist | 0.168 0.105 DBMET03083 0.14 0.126 DBMET01429 | DBMET03083 | |
| 0.074 | 0.013 | 0.074 | Carbonic anhydrase IV inhibitor | 0.058 0.02 DBMET03083 0.073 0.013 DBMET01429 | ||
| 0.118 | 0.059 | 0.161 | Photosensitizer | 0.131 0.045 DBMET03083 0.161 0.025 DBMET01429 | DBMET01429 | |
| 0.069 | 0.011 | 0.069 | Glutamate (mGluR1a) antagonist | 0.044 0.025 DBMET03083 0.05 0.02 DBMET01429 | ||
| 0.079 | 0.021 | 0.258 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.258 0.005 DBMET03083 0.105 0.013 DBMET01429 | DBMET03083 | |
| 0.076 | 0.018 | 0.16 | Carbonic anhydrase XIV inhibitor | 0.16 0.005 DBMET01429 | DBMET01429 | |
| 0.072 | 0.015 | 0.1 | Ryanodine receptor antagonist | 0.079 0.009 DBMET03083 0.1 0.004 DBMET01429 | DBMET01429 | |
| 0.087 | 0.032 | 0.106 | Carbonic anhydrase inhibitor | 0.054 0.051 DBMET03083 0.106 0.025 DBMET01429 | DBMET01429 | |
| 0.126 | 0.072 | 0.175 | Antibacterial (Helicobacter pylori) | 0.175 0.03 DBMET03083 | DBMET03083 | |
| 0.074 | 0.023 | 0.161 | NMDA 2A receptor antagonist | 0.161 0.006 DBMET01429 | DBMET01429 | |
| 0.084 | 0.033 | 0.084 | Neuronal nicotinic receptor antagonist | 0.078 0.039 DBMET03083 | ||
| 0.113 | 0.063 | 0.245 | DNA intercalator | 0.245 0.017 DBMET03083 | DBMET03083 | |
| 0.077 | 0.028 | 0.186 | Neuraminidase (influenza) inhibitor | 0.088 0.021 DBMET03083 0.186 0.005 DBMET01429 | DBMET01429 | |
| 0.054 | 0.006 | 0.097 | Methionyl aminopeptidase 2 inhibitor | 0.084 0.004 DBMET03083 0.097 0.004 DBMET01429 | DBMET01429 | |
| 0.06 | 0.013 | 0.06 | Benzodiazepine antagonist | 0.053 0.022 DBMET03083 | ||
| 0.184 | 0.136 | 0.528 | 5 Hydroxytryptamine release stimulant | 0.528 0.023 DBMET03083 0.296 0.071 DBMET01429 | DBMET03083 | |
| 0.126 | 0.079 | 0.181 | Alkaline phosphatase inhibitor | 0.146 0.062 DBMET03083 0.181 0.041 DBMET01429 | DBMET01429 | |
| 0.072 | 0.025 | 0.072 | Potassium channel intermediate-conductance Ca-activated blocker | 0.055 0.054 DBMET03083 0.065 0.034 DBMET01429 | ||
| 0.092 | 0.045 | 0.137 | Glutathione S-transferase inhibitor | 0.137 0.015 DBMET03083 0.101 0.037 DBMET01429 | DBMET03083 | |
| 0.076 | 0.031 | 0.096 | Beta adrenoreceptor antagonist | 0.096 0.018 DBMET03083 0.059 0.057 DBMET01429 | DBMET03083 | |
| 0.09 | 0.045 | 0.253 | D-Ala-D-Ala ligase inhibitor | 0.08 0.069 DBMET03083 0.253 0.003 DBMET01429 | DBMET01429 | |
| 0.076 | 0.032 | 0.106 | Potassium channel (ATP-sensitive) blocker | 0.106 0.013 DBMET03083 0.068 0.045 DBMET01429 | DBMET03083 | |
| 0.072 | 0.028 | 0.094 | Carbonic anhydrase I inhibitor | 0.094 0.02 DBMET01429 | DBMET01429 | |
| 0.118 | 0.076 | 0.16 | DNA repair enzyme inhibitor | 0.131 0.053 DBMET03083 0.16 0.024 DBMET01429 | DBMET01429 | |
| 0.057 | 0.015 | 0.09 | Neuraminidase (Influenza A) inhibitor | 0.079 0.005 DBMET03083 0.09 0.004 DBMET01429 | DBMET01429 | |
| 0.113 | 0.073 | 0.113 | Calcium channel N-type blocker | |||
| 0.06 | 0.019 | 0.076 | Purinergic P2Y antagonist | 0.047 0.029 DBMET03083 0.076 0.014 DBMET01429 | DBMET01429 | |
| 0.071 | 0.031 | 0.223 | Purinergic P2X1 antagonist | 0.072 0.03 DBMET03083 0.223 0.003 DBMET01429 | DBMET01429 | |
| 0.098 | 0.058 | 0.227 | Prolactin inhibitor | 0.227 0.005 DBMET03083 0.098 0.057 DBMET01429 | DBMET03083 | |
| 0.107 | 0.068 | 0.202 | Mucolytic | 0.167 0.024 DBMET03083 0.202 0.013 DBMET01429 | DBMET01429 | |
| 0.1 | 0.062 | 0.39 | Carbonic anhydrase III inhibitor | 0.13 0.038 DBMET03083 0.39 0.004 DBMET01429 | DBMET01429 | |
| 0.052 | 0.013 | 0.27 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.049 0.016 DBMET03083 0.27 0.001 DBMET01429 | DBMET01429 | |
| 0.071 | 0.033 | 0.161 | Neuraminidase inhibitor | 0.081 0.024 DBMET03083 0.161 0.005 DBMET01429 | DBMET01429 | |
| 0.089 | 0.051 | 0.145 | Myeloperoxidase inhibitor | 0.145 0.012 DBMET03083 0.128 0.016 DBMET01429 | DBMET03083 | |
| 0.041 | 0.005 | 0.076 | Estrogen-related receptor gamma antagonist | 0.076 0.002 DBMET03083 0.035 0.008 DBMET01429 | DBMET03083 | |
| 0.08 | 0.043 | 0.08 | Adenosine A3 receptor antagonist | 0.067 0.064 DBMET03083 0.071 0.056 DBMET01429 | ||
| 0.058 | 0.022 | 0.085 | Adenosine deaminase inhibitor | 0.072 0.012 DBMET03083 0.085 0.008 DBMET01429 | DBMET01429 | |
| 0.125 | 0.089 | 0.196 | Lipid peroxidase inhibitor | 0.196 0.043 DBMET03083 | DBMET03083 | |
| 0.043 | 0.009 | 0.043 | Dopamine autoreceptor agonist | 0.04 0.009 DBMET03083 | ||
| 0.066 | 0.032 | 0.085 | Carbonic anhydrase II inhibitor | 0.085 0.023 DBMET01429 | DBMET01429 | |
| 0.067 | 0.034 | 0.067 | Transcription factor AP-1 inhibitor | |||
| 0.193 | 0.16 | 0.248 | Hypoxia-inducible factor 1 alpha inhibitor | 0.222 0.127 DBMET03083 0.248 0.103 DBMET01429 | DBMET01429 | |
| 0.057 | 0.024 | 0.139 | Topoisomerase II beta inhibitor | 0.109 0.008 DBMET03083 0.139 0.005 DBMET01429 | DBMET01429 | |
| 0.197 | 0.164 | 0.197 | Thyroid hormone antagonist | |||
| 0.077 | 0.044 | 0.457 | Histidine decarboxylase inhibitor | 0.091 0.036 DBMET03083 0.457 0.003 DBMET01429 | DBMET01429 | |
| 0.068 | 0.035 | 0.211 | NMDA 2C receptor antagonist | 0.087 0.021 DBMET03083 0.211 0.005 DBMET01429 | DBMET01429 | |
| 0.043 | 0.011 | 0.076 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.076 0.005 DBMET03083 0.049 0.009 DBMET01429 | DBMET03083 | |
| 0.048 | 0.016 | 0.13 | Retinoic acid alpha receptor agonist | 0.13 0.003 DBMET01429 | DBMET01429 | |
| 0.064 | 0.036 | 0.071 | Acetylcholine M3 receptor antagonist | 0.071 0.031 DBMET03083 | DBMET03083 | |
| 0.19 | 0.162 | 0.269 | 12-Lipoxygenase inhibitor | 0.269 0.099 DBMET01429 | DBMET01429 | |
| 0.074 | 0.047 | 0.195 | Glycine receptor agonist | 0.127 0.011 DBMET03083 0.195 0.004 DBMET01429 | DBMET01429 | |
| 0.057 | 0.029 | 0.351 | Aconitate hydratase inhibitor | 0.082 0.013 DBMET03083 0.351 0.002 DBMET01429 | DBMET01429 | |
| 0.063 | 0.035 | 0.063 | Dopamine uptake inhibitor | |||
| 0.052 | 0.025 | 0.064 | Cytokine production stimulant | 0.064 0.01 DBMET03083 0.046 0.04 DBMET01429 | DBMET03083 | |
| 0.064 | 0.037 | 0.075 | Acetylcholine M5 receptor antagonist | 0.075 0.027 DBMET03083 | DBMET03083 | |
| 0.079 | 0.052 | 0.12 | Macrophage migration inhibitory factor inhibitor | 0.08 0.052 DBMET03083 0.12 0.025 DBMET01429 | DBMET01429 | |
| 0.066 | 0.04 | 0.116 | Beta 3 adrenoreceptor antagonist | 0.116 0.011 DBMET03083 0.07 0.034 DBMET01429 | DBMET03083 | |
| 0.084 | 0.057 | 0.084 | GABA A receptor agonist | 0.077 0.068 DBMET03083 | ||
| 0.053 | 0.029 | 0.139 | Phosphorylase inhibitor | 0.068 0.021 DBMET03083 0.139 0.008 DBMET01429 | DBMET01429 | |
| 0.063 | 0.039 | 0.075 | Prolactin release inhibitor | 0.075 0.016 DBMET03083 0.059 0.055 DBMET01429 | DBMET03083 | |
| 0.028 | 0.005 | 0.046 | Neuraminidase (Influenza B) inhibitor | 0.034 0.004 DBMET03083 0.046 0.003 DBMET01429 | DBMET01429 | |
| 0.072 | 0.049 | 0.136 | Phospholipase D inhibitor | 0.136 0.004 DBMET03083 0.086 0.027 DBMET01429 | DBMET03083 | |
| 0.077 | 0.054 | 0.111 | MAP kinase kinase 7 inhibitor | 0.107 0.008 DBMET03083 0.111 0.006 DBMET01429 | DBMET01429 | |
| 0.073 | 0.05 | 0.1 | Telomerase inhibitor | 0.1 0.033 DBMET03083 | DBMET03083 | |
| 0.047 | 0.024 | 0.146 | Glutamate (mGluR4) antagonist | 0.041 0.036 DBMET03083 0.146 0.004 DBMET01429 | DBMET01429 | |
| 0.08 | 0.058 | 0.112 | Adrenaline agonist | 0.105 0.034 DBMET03083 0.112 0.03 DBMET01429 | DBMET01429 | |
| 0.059 | 0.037 | 0.294 | Argininosuccinate synthase inhibitor | 0.112 0.017 DBMET03083 0.294 0.004 DBMET01429 | DBMET01429 | |
| 0.026 | 0.005 | 0.049 | Estrogen-related receptor gamma agonist | 0.049 0.003 DBMET03083 0.021 0.009 DBMET01429 | DBMET03083 | |
| 0.046 | 0.026 | 0.143 | Glutamate (mGluR group III) antagonist | 0.143 0.004 DBMET01429 | DBMET01429 | |
| 0.04 | 0.021 | 0.208 | Glutamate (mGluR3) antagonist | 0.035 0.028 DBMET03083 0.208 0.003 DBMET01429 | DBMET01429 | |
| 0.092 | 0.074 | 0.092 | Alpha 2c adrenoreceptor antagonist | |||
| 0.054 | 0.037 | 0.054 | Nicotinic receptor alpha7 subunit antagonist | 0.051 0.042 DBMET03083 | ||
| 0.04 | 0.023 | 0.148 | Glutamate (mGluR8) agonist | 0.042 0.02 DBMET03083 0.148 0.002 DBMET01429 | DBMET01429 | |
| 0.07 | 0.054 | 0.334 | Glutamate decarboxylase inhibitor | 0.148 0.013 DBMET03083 0.334 0.003 DBMET01429 | DBMET01429 | |
| 0.09 | 0.074 | 0.143 | Bile acid receptor antagonist | 0.092 0.067 DBMET03083 0.143 0.009 DBMET01429 | DBMET01429 | |
| 0.045 | 0.029 | 0.09 | Geranyltranstransferase inhibitor | 0.09 0.004 DBMET03083 0.068 0.009 DBMET01429 | DBMET03083 | |
| 0.081 | 0.066 | 0.103 | Transcription factor NF kappa B stimulant | 0.103 0.036 DBMET01429 | DBMET01429 | |
| 0.037 | 0.022 | 0.109 | Phosphoglycerate kinase inhibitor | 0.109 0.006 DBMET03083 0.077 0.009 DBMET01429 | DBMET03083 | |
| 0.073 | 0.059 | 0.14 | GABA B receptor agonist | 0.09 0.026 DBMET03083 0.14 0.005 DBMET01429 | DBMET01429 | |
| 0.052 | 0.038 | 0.192 | Ornithine carbamoyltransferase inhibitor | 0.129 0.012 DBMET03083 0.192 0.007 DBMET01429 | DBMET01429 | |
| 0.044 | 0.03 | 0.067 | Dihydrofolate reductase inhibitor | 0.067 0.007 DBMET01429 | DBMET01429 | |
| 0.149 | 0.135 | 0.255 | Insulin sensitizer | 0.188 0.086 DBMET03083 0.255 0.032 DBMET01429 | DBMET01429 | |
| 0.128 | 0.115 | 0.225 | Interferon gamma antagonist | 0.17 0.057 DBMET03083 0.225 0.034 DBMET01429 | DBMET01429 | |
| 0.037 | 0.024 | 0.11 | Retinoid X receptor agonist | 0.046 0.02 DBMET03083 0.11 0.004 DBMET01429 | DBMET01429 | |
| 0.1 | 0.086 | 0.216 | Topoisomerase II inhibitor | 0.216 0.03 DBMET03083 0.158 0.046 DBMET01429 | DBMET03083 | |
| 0.045 | 0.032 | 0.051 | Beta adrenoreceptor agonist | 0.048 0.023 DBMET03083 0.051 0.016 DBMET01429 | DBMET01429 | |
| 0.06 | 0.048 | 0.073 | Beta 2 adrenoreceptor agonist | 0.073 0.015 DBMET03083 0.065 0.03 DBMET01429 | DBMET03083 | |
| 0.044 | 0.032 | 0.087 | Fructose-1,6-bisphosphatase inhibitor | 0.087 0.005 DBMET01429 | DBMET01429 | |
| 0.052 | 0.041 | 0.13 | Maillard reaction inhibitor | 0.13 0.008 DBMET01429 | DBMET01429 | |
| 0.053 | 0.042 | 0.207 | Carbonic anhydrase VB inhibitor | 0.072 0.027 DBMET03083 0.207 0.005 DBMET01429 | DBMET01429 | |
| 0.218 | 0.207 | 0.249 | Alpha-glucosidase inhibitor | 0.249 0.188 DBMET01429 | DBMET01429 | |
| 0.091 | 0.08 | 0.218 | Expectorant | 0.136 0.041 DBMET03083 0.218 0.017 DBMET01429 | DBMET01429 | |
| 0.025 | 0.015 | 0.025 | 5 Hydroxytryptamine 4 agonist | |||
| 0.054 | 0.045 | 0.054 | Acetyl-CoA transferase 2 inhibitor | |||
| 0.034 | 0.025 | 0.136 | Retinoid X alpha receptor agonist | 0.045 0.016 DBMET03083 0.136 0.003 DBMET01429 | DBMET01429 | |
| 0.059 | 0.05 | 0.06 | Nitric oxide donor | 0.06 0.049 DBMET03083 | DBMET03083 | |
| 0.114 | 0.105 | 0.129 | Neurotrophic factor | 0.129 0.081 DBMET03083 0.129 0.082 DBMET01429 | DBMET01429 | |
| 0.033 | 0.025 | 0.035 | Benzodiazepine receptor peripheral-type antagonist | 0.035 0.021 DBMET03083 | DBMET03083 | |
| 0.017 | 0.009 | 0.017 | CDK2/cyclin A3 inhibitor | 0.017 0.01 DBMET03083 | ||
| 0.033 | 0.026 | 0.058 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.058 0.006 DBMET03083 0.04 0.016 DBMET01429 | DBMET03083 | |
| 0.053 | 0.046 | 0.06 | Adenosine A1 receptor antagonist | 0.058 0.041 DBMET03083 0.06 0.039 DBMET01429 | DBMET01429 | |
| 0.014 | 0.008 | 0.021 | Cyclin D2 inhibitor | 0.021 0.004 DBMET03083 | DBMET03083 | |
| 0.054 | 0.048 | 0.079 | Sphingosine 1-phosphate receptor 3 antagonist | 0.059 0.039 DBMET03083 0.079 0.017 DBMET01429 | DBMET01429 | |
| 0.055 | 0.049 | 0.201 | Carbamoyl phosphate synthetase inhibitor | 0.201 0.007 DBMET03083 0.153 0.011 DBMET01429 | DBMET03083 | |
| 0.061 | 0.055 | 0.251 | Phosphofructokinase-1 inhibitor | 0.194 0.012 DBMET03083 0.251 0.007 DBMET01429 | DBMET01429 | |
| 0.018 | 0.012 | 0.027 | Methylmalonyl-CoA mutase inhibitor | 0.023 0.005 DBMET03083 0.027 0.003 DBMET01429 | DBMET01429 | |
| 0.076 | 0.071 | 0.214 | NMDA receptor antagonist | 0.079 0.067 DBMET03083 0.214 0.012 DBMET01429 | DBMET01429 | |
| 0.016 | 0.013 | 0.032 | Ileal bile acid transport inhibitor | 0.032 0.005 DBMET03083 0.015 0.014 DBMET01429 | DBMET03083 | |
| 0.032 | 0.029 | 0.082 | Arginase inhibitor | 0.082 0.005 DBMET03083 0.074 0.007 DBMET01429 | DBMET03083 | |
| 0.098 | 0.095 | 0.147 | Microtubule formation inhibitor | 0.135 0.047 DBMET03083 0.147 0.039 DBMET01429 | DBMET01429 | |
| 0.055 | 0.052 | 0.055 | Potassium channel (Ca-activated) blocker | |||
| 0.073 | 0.07 | 0.13 | Glycine receptor antagonist | 0.13 0.014 DBMET03083 0.099 0.034 DBMET01429 | DBMET03083 | |
| 0.093 | 0.09 | 0.193 | Protein kinase C gamma inhibitor | 0.104 0.07 DBMET03083 0.193 0.015 DBMET01429 | DBMET01429 | |
| 0.019 | 0.017 | 0.027 | Toll-Like receptor 8 agonist | 0.027 0.005 DBMET03083 | DBMET03083 | |
| 0.044 | 0.042 | 0.089 | Carbonic anhydrase XII inhibitor | 0.089 0.022 DBMET01429 | DBMET01429 | |
| 0.06 | 0.059 | 0.072 | Calcium channel P-type blocker | 0.072 0.025 DBMET03083 0.063 0.046 DBMET01429 | DBMET03083 | |
| 0.035 | 0.035 | 0.079 | GABA uptake inhibitor | 0.075 0.006 DBMET03083 0.079 0.005 DBMET01429 | DBMET01429 | |
| 0.092 | 0.092 | 0.147 | Interleukin 1b antagonist | 0.147 0.042 DBMET01429 | DBMET01429 | |
| 0.032 | 0.031 | 0.04 | Opioid delta receptor agonist | 0.04 0.019 DBMET03083 | DBMET03083 | |
| 0.021 | 0.021 | 0.038 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.038 0.005 DBMET01429 | DBMET01429 | |
| 0.003 | 0.004 | 0.006 | Reverse transcriptase (HBV) inhibitor | 0.006 0.002 DBMET03083 | DBMET03083 | |
| 0.147 | 0.149 | 0.171 | Growth factor agonist | 0.171 0.101 DBMET03083 | DBMET03083 | |
| 0.039 | 0.041 | 0.118 | AICAR transformylase inhibitor | 0.118 0.004 DBMET01429 | DBMET01429 | |
| 0.113 | 0.115 | 0.171 | Sphingosine 1-phosphate receptor 2 antagonist | 0.171 0.021 DBMET03083 0.166 0.024 DBMET01429 | DBMET03083 | |
| 0.033 | 0.036 | 0.24 | Kainate receptor antagonist | 0.24 0.004 DBMET01429 | DBMET01429 | |
| 0.078 | 0.081 | 0.31 | HIV-1 integrase (Overall Integration) inhibitor | 0.098 0.057 DBMET03083 0.31 0.003 DBMET01429 | DBMET01429 | |
| 0.059 | 0.062 | 0.203 | Potassium channel large-conductance Ca-activated activator | 0.203 0.006 DBMET01429 | DBMET01429 | |
| 0.068 | 0.072 | 0.075 | Platelet growth factor antagonist | 0.075 0.062 DBMET03083 | DBMET03083 | |
| 0.12 | 0.125 | 0.203 | Sphingosine 1-phosphate receptor 5 antagonist | 0.17 0.034 DBMET03083 0.203 0.01 DBMET01429 | DBMET01429 | |
| 0.04 | 0.044 | 0.152 | AMPA receptor antagonist | 0.152 0.005 DBMET01429 | DBMET01429 | |
| 0.091 | 0.096 | 0.222 | DOPA decarboxylase inhibitor | 0.128 0.036 DBMET03083 0.222 0.005 DBMET01429 | DBMET01429 | |
| 0.046 | 0.052 | 0.071 | Beta 1 adrenoreceptor antagonist | 0.071 0.025 DBMET03083 | DBMET03083 | |
| 0.035 | 0.041 | 0.058 | Leukocyte elastase inhibitor | 0.058 0.019 DBMET01429 | DBMET01429 | |
| 0.099 | 0.105 | 0.167 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.167 0.057 DBMET03083 | DBMET03083 | |
| 0.067 | 0.073 | 0.087 | Potassium channel (Tandem pore domain) blocker | 0.087 0.021 DBMET03083 | DBMET03083 | |
| 0.019 | 0.026 | 0.096 | Retinoic acid receptor agonist | 0.096 0.004 DBMET01429 | DBMET01429 | |
| 0.044 | 0.051 | 0.237 | CD45 antagonist | 0.237 0.004 DBMET01429 | DBMET01429 | |
| 0.063 | 0.071 | 0.088 | CYP2A6 inhibitor | 0.088 0.043 DBMET03083 | DBMET03083 | |
| 0.037 | 0.045 | 0.063 | GABA B receptor antagonist | 0.063 0.011 DBMET01429 | DBMET01429 | |
| 0.105 | 0.113 | 0.218 | Protein kinase stimulant | 0.158 0.063 DBMET03083 0.218 0.036 DBMET01429 | DBMET01429 | |
| 0.048 | 0.058 | 0.089 | Carbonic anhydrase stimulant | 0.089 0.022 DBMET03083 0.06 0.041 DBMET01429 | DBMET03083 | |
| 0.239 | 0.248 | 0.272 | MAP kinase 1 inhibitor | 0.272 0.21 DBMET03083 | DBMET03083 | |
| 0.108 | 0.118 | 0.153 | Papain-like protease (SARS coronavirus) inhibitor | 0.153 0.031 DBMET01429 | DBMET01429 | |
| 0.031 | 0.041 | 0.047 | Adenosine uptake inhibitor | 0.047 0.005 DBMET03083 | DBMET03083 | |
| 0.119 | 0.129 | 0.183 | Heat shock protein 90 alpha antagonist | 0.183 0.061 DBMET01429 | DBMET01429 | |
| 0.02 | 0.03 | 0.055 | Lysophosphatidic acid receptor 1 agonist | 0.055 0.004 DBMET03083 0.026 0.015 DBMET01429 | DBMET03083 | |
| 0.018 | 0.029 | 0.05 | Retinoic acid gamma receptor agonist | 0.05 0.003 DBMET01429 | DBMET01429 | |
| 0.036 | 0.047 | 0.085 | Nerve growth factor antagonist | 0.085 0.004 DBMET01429 | DBMET01429 | |
| 0.016 | 0.027 | 0.087 | Retinoic acid beta receptor agonist | 0.087 0.003 DBMET01429 | DBMET01429 | |
| 0.127 | 0.138 | 0.281 | Angiogenesis stimulant | 0.281 0.056 DBMET01429 | DBMET01429 | |
| 0.076 | 0.089 | 0.414 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.169 0.022 DBMET03083 0.414 0.004 DBMET01429 | DBMET01429 | |
| 0.043 | 0.055 | 0.091 | Acetylcholine muscarinic agonist | 0.091 0.019 DBMET03083 | DBMET03083 | |
| 0.034 | 0.047 | 0.052 | Plasmepsin II inhibitor | 0.052 0.017 DBMET03083 | DBMET03083 | |
| 0.031 | 0.045 | 0.066 | Membrane dipeptidase inhibitor | 0.066 0.008 DBMET03083 0.066 0.008 DBMET01429 | DBMET01429 | |
| 0.07 | 0.084 | 0.153 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.153 0.014 DBMET01429 | DBMET01429 | |
| 0.032 | 0.046 | 0.145 | AMPA 4 receptor antagonist | 0.042 0.023 DBMET03083 0.145 0.004 DBMET01429 | DBMET01429 | |
| 0.207 | 0.221 | 0.461 | Antibacterial | 0.248 0.179 DBMET03083 0.461 0.053 DBMET01429 | DBMET01429 | |
| 0.135 | 0.15 | 0.155 | Platelet aggregation inhibitor | 0.155 0.123 DBMET03083 | DBMET03083 | |
| 0.031 | 0.045 | 0.061 | Oxytocin agonist | 0.061 0.016 DBMET03083 | DBMET03083 | |
| 0.019 | 0.034 | 0.05 | Lysine carboxypeptidase inhibitor | 0.039 0.011 DBMET03083 0.05 0.008 DBMET01429 | DBMET01429 | |
| 0.029 | 0.044 | 0.07 | Toll-Like receptor 2 agonist | 0.07 0.018 DBMET03083 | DBMET03083 | |
| 0.023 | 0.039 | 0.034 | Calcitonin receptor agonist | 0.034 0.023 DBMET03083 | DBMET03083 | |
| 0.008 | 0.024 | 0.043 | Lysophosphatidic acid receptor 3 agonist | 0.043 0.003 DBMET03083 | DBMET03083 | |
| 0.057 | 0.073 | 0.085 | Protein kinase C beta inhibitor | 0.083 0.026 DBMET03083 0.085 0.024 DBMET01429 | DBMET01429 | |
| 0.066 | 0.082 | 0.077 | Bcr-Abl kinase inhibitor | 0.077 0.068 DBMET01429 | DBMET01429 | |
| 0.027 | 0.044 | 0.12 | Factor XIIIa inhibitor | 0.12 0.005 DBMET03083 | DBMET03083 | |
| 0.015 | 0.033 | 0.083 | Retinoid X gamma receptor agonist | 0.083 0.004 DBMET01429 | DBMET01429 | |
| 0.078 | 0.096 | 0.115 | Interleukin 1 beta converting enzyme inhibitor | 0.115 0.04 DBMET03083 0.095 0.064 DBMET01429 | DBMET03083 | |
| 0.114 | 0.132 | 0.159 | Thiol protease inhibitor | 0.145 0.074 DBMET03083 0.159 0.062 DBMET01429 | DBMET01429 | |
| 0.043 | 0.061 | 0.079 | Leukotriene B4 antagonist | 0.053 0.038 DBMET03083 0.079 0.016 DBMET01429 | DBMET01429 | |
| 0.05 | 0.069 | 0.148 | Sphingosine 1-phosphate receptor 4 agonist | 0.148 0.009 DBMET03083 0.085 0.033 DBMET01429 | DBMET03083 | |
| 0.026 | 0.046 | 0.077 | Glutamate (mGluR3) agonist | 0.036 0.014 DBMET03083 0.077 0.003 DBMET01429 | DBMET01429 | |
| 0.083 | 0.103 | 0.139 | Beta glucuronidase inhibitor | 0.139 0.031 DBMET03083 0.103 0.065 DBMET01429 | DBMET03083 | |
| 0.148 | 0.168 | 0.203 | Antioxidant | 0.203 0.112 DBMET03083 0.186 0.126 DBMET01429 | DBMET03083 | |
| 0.025 | 0.045 | 0.137 | NMDA receptor subunit 3A antagonist | 0.137 0.005 DBMET01429 | DBMET01429 | |
| 0.019 | 0.04 | 0.053 | Glutamate (mGluR1) agonist | 0.026 0.015 DBMET03083 0.053 0.005 DBMET01429 | DBMET01429 | |
| 0.042 | 0.063 | 0.05 | Myc inhibitor | 0.05 0.046 DBMET01429 | DBMET01429 | |
| 0.111 | 0.133 | 0.362 | Hexokinase inhibitor | 0.133 0.101 DBMET03083 0.362 0.005 DBMET01429 | DBMET01429 | |
| 0.035 | 0.056 | 0.088 | Carbonic anhydrase IX inhibitor | 0.088 0.024 DBMET01429 | DBMET01429 | |
| 0.025 | 0.047 | 0.05 | Purinergic P2Y2 antagonist | 0.05 0.01 DBMET01429 | DBMET01429 | |
| 0.076 | 0.098 | 0.174 | ABCA1 expression enhancer | 0.174 0.013 DBMET01429 | DBMET01429 | |
| 0.01 | 0.032 | 0.018 | Adenosine A2 receptor agonist | 0.018 0.009 DBMET03083 0.015 0.013 DBMET01429 | DBMET03083 | |
| 0.038 | 0.061 | 0.092 | Lysophosphatidic acid 3 receptor antagonist | 0.057 0.026 DBMET03083 0.092 0.006 DBMET01429 | DBMET01429 | |
| 0.058 | 0.081 | 0.077 | Exportin-1 inhibitor | 0.077 0.029 DBMET03083 0.066 0.052 DBMET01429 | DBMET03083 | |
| 0.025 | 0.049 | 0.047 | Diamine oxidase inhibitor | 0.047 0.017 DBMET03083 0.044 0.019 DBMET01429 | DBMET03083 | |
| 0.086 | 0.11 | 0.137 | Beta amyloid protein antagonist | 0.137 0.051 DBMET01429 | DBMET01429 | |
| 0.048 | 0.072 | 0.074 | Immunoglobulin Fc receptor antagonist | 0.061 0.023 DBMET03083 0.074 0.008 DBMET01429 | DBMET01429 | |
| 0.136 | 0.161 | 0.275 | Neurotrophic factor enhancer | 0.194 0.082 DBMET03083 0.275 0.026 DBMET01429 | DBMET01429 | |
| 0.105 | 0.131 | 0.148 | Vanilloid 1 agonist | 0.148 0.04 DBMET03083 0.118 0.094 DBMET01429 | DBMET03083 | |
| 0.042 | 0.068 | 0.062 | Nicotinic alpha3beta2 receptor antagonist | 0.062 0.024 DBMET03083 | DBMET03083 | |
| 0.041 | 0.067 | 0.095 | 5 Hydroxytryptamine 1B agonist | 0.095 0.008 DBMET03083 | DBMET03083 | |
| 0.022 | 0.048 | 0.092 | Growth hormone secretagogue receptor antagonist | 0.092 0.008 DBMET03083 | DBMET03083 | |
| 0.025 | 0.052 | 0.036 | Carboxypeptidase B inhibitor | 0.036 0.017 DBMET01429 | DBMET01429 | |
| 0.012 | 0.039 | 0.035 | 5-Alpha-reductase 2 inhibitor | 0.018 0.015 DBMET03083 0.035 0.008 DBMET01429 | DBMET01429 | |
| 0.015 | 0.042 | 0.033 | Retinoid X beta receptor antagonist | 0.024 0.009 DBMET03083 0.033 0.004 DBMET01429 | DBMET01429 | |
| 0.035 | 0.062 | 0.05 | Beta 2 adrenoreceptor antagonist | 0.05 0.036 DBMET03083 0.046 0.043 DBMET01429 | DBMET03083 | |
| 0.009 | 0.036 | 0.032 | Carbonic anhydrase X inhibitor | 0.02 0.009 DBMET03083 0.032 0.004 DBMET01429 | DBMET01429 | |
| 0.009 | 0.036 | 0.032 | Carbonic anhydrase VIII inhibitor | 0.02 0.009 DBMET03083 0.032 0.004 DBMET01429 | DBMET01429 | |
| 0.021 | 0.049 | 0.134 | Fumarate hydratase inhibitor | 0.059 0.01 DBMET03083 0.134 0.004 DBMET01429 | DBMET01429 | |
| 0.007 | 0.035 | 0.015 | Adenosine A2a receptor agonist | 0.015 0.011 DBMET03083 | DBMET03083 | |
| 0.019 | 0.048 | 0.079 | Leukotriene A4 hydrolase inhibitor | 0.079 0.009 DBMET01429 | DBMET01429 | |
| 0.036 | 0.064 | 0.141 | Xanthine dehydrogenase inhibitor | 0.141 0.008 DBMET01429 | DBMET01429 | |
| 0.043 | 0.071 | 0.17 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.17 0.005 DBMET01429 | DBMET01429 | |
| 0.124 | 0.152 | 0.165 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.165 0.099 DBMET01429 | DBMET01429 | |
| 0.042 | 0.072 | 0.068 | Thromboxane synthase inhibitor | 0.068 0.019 DBMET01429 | DBMET01429 | |
| 0.046 | 0.076 | 0.105 | Adenine nucleotide translocase inhibitor | 0.105 0.004 DBMET01429 | DBMET01429 | |
| 0.07 | 0.101 | 0.089 | Phosphodiesterase I inhibitor | 0.089 0.059 DBMET03083 0.084 0.069 DBMET01429 | DBMET03083 | |
| 0.018 | 0.048 | 0.091 | NMDA 2D receptor antagonist | 0.091 0.004 DBMET01429 | DBMET01429 | |
| 0.003 | 0.034 | 0.015 | Mannitol 2-dehydrogenase inhibitor | 0.01 0.005 DBMET03083 0.015 0.003 DBMET01429 | DBMET01429 | |
| 0.062 | 0.093 | 0.08 | Chymotrypsin inhibitor | 0.08 0.055 DBMET01429 | DBMET01429 | |
| 0.01 | 0.041 | 0.015 | Purinergic P2Y1 agonist | 0.015 0.012 DBMET03083 0.015 0.011 DBMET01429 | DBMET01429 | |
| 0.072 | 0.104 | 0.094 | Thioredoxin inhibitor | 0.094 0.055 DBMET01429 | DBMET01429 | |
| 0.008 | 0.04 | 0.027 | 5-Alpha-reductase 1 inhibitor | 0.027 0.009 DBMET01429 | DBMET01429 | |
| 0.118 | 0.15 | 0.224 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.224 0.01 DBMET01429 | DBMET01429 | |
| 0.03 | 0.062 | 0.078 | Thymidine kinase inhibitor | 0.078 0.009 DBMET03083 0.039 0.032 DBMET01429 | DBMET03083 | |
| 0.02 | 0.053 | 0.039 | Purinergic P2Y15 antagonist | 0.039 0.007 DBMET03083 0.031 0.015 DBMET01429 | DBMET03083 | |
| 0.011 | 0.043 | 0.026 | Vitamin D receptor agonist | 0.026 0.004 DBMET03083 | DBMET03083 | |
| 0.037 | 0.071 | 0.066 | Glutamate (mGluR1) antagonist | 0.066 0.033 DBMET01429 | DBMET01429 | |
| 0.079 | 0.113 | 0.108 | Phosphodiesterase 6D inhibitor | 0.108 0.039 DBMET03083 0.097 0.057 DBMET01429 | DBMET03083 | |
| 0.021 | 0.054 | 0.043 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.043 0.004 DBMET03083 | DBMET03083 | |
| 0.05 | 0.084 | 0.069 | Phosphodiesterase 1C inhibitor | 0.064 0.04 DBMET03083 0.069 0.03 DBMET01429 | DBMET01429 | |
| 0.012 | 0.046 | 0.076 | Retinoid X beta receptor agonist | 0.076 0.004 DBMET01429 | DBMET01429 | |
| 0.013 | 0.048 | 0.026 | Antibiotic Anthracycline-like | 0.026 0.005 DBMET03083 0.019 0.014 DBMET01429 | DBMET03083 | |
| 0.134 | 0.169 | 0.182 | Free radical scavenger | 0.158 0.135 DBMET03083 0.182 0.113 DBMET01429 | DBMET01429 | |
| 0.066 | 0.102 | 0.241 | Monophenol monooxygenase inhibitor | 0.091 0.083 DBMET03083 0.241 0.025 DBMET01429 | DBMET01429 | |
| 0.008 | 0.043 | 0.014 | NMDA receptor phencyclidine site antagonist | 0.014 0.013 DBMET03083 | DBMET03083 | |
| 0.017 | 0.053 | 0.045 | Calcium-sensing receptor agonist | 0.045 0.006 DBMET01429 | DBMET01429 | |
| 0.063 | 0.099 | 0.091 | Inducible nitric-oxide synthase inhibitor | 0.091 0.046 DBMET01429 | DBMET01429 | |
| 0.019 | 0.055 | 0.024 | Complement factor 1r inhibitor | 0.024 0.022 DBMET01429 | DBMET01429 | |
| 0.05 | 0.086 | 0.11 | Na+ K+ transporting ATPase inhibitor | 0.11 0.023 DBMET03083 0.076 0.054 DBMET01429 | DBMET03083 | |
| 0.118 | 0.155 | 0.164 | Hepatoprotectant | 0.164 0.095 DBMET01429 | DBMET01429 | |
| 0.015 | 0.052 | 0.032 | Liver X receptor beta antagonist | 0.032 0.017 DBMET03083 0.031 0.018 DBMET01429 | DBMET03083 | |
| 0.028 | 0.065 | 0.034 | ATM kinase inhibitor | 0.034 0.031 DBMET03083 | DBMET03083 | |
| 0.054 | 0.091 | 0.067 | Nicotinic alpha4beta2 receptor antagonist | 0.067 0.065 DBMET01429 | DBMET01429 | |
| 0.029 | 0.067 | 0.082 | Thymidylate synthase inhibitor | 0.053 0.024 DBMET03083 0.082 0.007 DBMET01429 | DBMET01429 | |
| 0.013 | 0.051 | 0.029 | Beta 1 adrenoreceptor agonist | 0.029 0.009 DBMET01429 | DBMET01429 | |
| 0.026 | 0.064 | 0.064 | Delayed rectifier potassium channel blocker | 0.064 0.006 DBMET03083 | DBMET03083 | |
| 0.128 | 0.166 | 0.183 | Neurotensin receptor agonist | 0.16 0.079 DBMET03083 0.183 0.047 DBMET01429 | DBMET01429 | |
| 0.035 | 0.074 | 0.062 | H+/K+-transporting ATPase inhibitor | 0.062 0.023 DBMET03083 | DBMET03083 | |
| 0.072 | 0.112 | 0.125 | Protein kinase C zeta inhibitor | 0.125 0.029 DBMET01429 | DBMET01429 | |
| 0.013 | 0.053 | 0.029 | Lysophosphatidic acid 1 receptor antagonist | 0.029 0.007 DBMET01429 | DBMET01429 | |
| 0.024 | 0.064 | 0.036 | Melatonin receptor 1A agonist | 0.036 0.018 DBMET03083 | DBMET03083 | |
| 0.043 | 0.084 | 0.188 | Carbonic anhydrase V inhibitor | 0.061 0.052 DBMET03083 0.188 0.008 DBMET01429 | DBMET01429 | |
| 0.025 | 0.066 | 0.037 | CDK5/p25 inhibitor | 0.037 0.035 DBMET03083 | DBMET03083 | |
| 0.05 | 0.092 | 0.065 | Trypsin inhibitor | 0.065 0.038 DBMET01429 | DBMET01429 | |
| 0.081 | 0.123 | 0.17 | MAP kinase kinase inhibitor | 0.157 0.048 DBMET03083 0.17 0.041 DBMET01429 | DBMET01429 | |
| 0.036 | 0.077 | 0.06 | Dopamine beta hydroxylase inhibitor | 0.055 0.022 DBMET03083 0.06 0.015 DBMET01429 | DBMET01429 | |
| 0.021 | 0.063 | 0.047 | Carnitine palmitoyltransferase inhibitor | 0.047 0.01 DBMET01429 | DBMET01429 | |
| 0.017 | 0.059 | 0.051 | LFA antagonist | 0.032 0.014 DBMET03083 0.051 0.005 DBMET01429 | DBMET01429 | |
| 0.02 | 0.063 | 0.062 | TRPM8 blocker | 0.042 0.022 DBMET03083 0.062 0.011 DBMET01429 | DBMET01429 | |
| 0.098 | 0.141 | 0.245 | Cell wall synthesis inhibitor | 0.21 0.026 DBMET03083 0.245 0.017 DBMET01429 | DBMET01429 | |
| 0.017 | 0.06 | 0.035 | Vanilloid 2 agonist | 0.028 0.012 DBMET03083 0.035 0.005 DBMET01429 | DBMET01429 | |
| 0.073 | 0.116 | 0.19 | Xanthine oxidase inhibitor | 0.19 0.022 DBMET01429 | DBMET01429 | |
| 0.041 | 0.085 | 0.142 | Dihydroorotate oxidase inhibitor | 0.142 0.003 DBMET01429 | DBMET01429 | |
| 0.068 | 0.113 | 0.092 | Bromodomain-containing protein 2 inhibitor | 0.092 0.051 DBMET03083 | DBMET03083 | |
| 0.061 | 0.105 | 0.091 | Acetylcholine agonist | 0.091 0.054 DBMET03083 | DBMET03083 | |
| 0.006 | 0.051 | 0.017 | Human herpes virus 5 capsid protein P40 inhibitor | 0.017 0.005 DBMET01429 | DBMET01429 | |
| 0.023 | 0.068 | 0.037 | DNA gyrase subunit B inhibitor | 0.037 0.027 DBMET01429 | DBMET01429 | |
| 0.021 | 0.066 | 0.046 | Carnitine palmitoyltransferase 1 inhibitor | 0.046 0.01 DBMET01429 | DBMET01429 | |
| 0.042 | 0.088 | 0.192 | NMDA 2 receptor antagonist | 0.192 0.01 DBMET01429 | DBMET01429 | |
| 0.07 | 0.116 | 0.13 | Hematopoietic | 0.13 0.019 DBMET03083 0.098 0.038 DBMET01429 | DBMET03083 | |
| 0.023 | 0.069 | 0.054 | Retinoid X alpha receptor antagonist | 0.036 0.02 DBMET03083 0.054 0.005 DBMET01429 | DBMET01429 | |
| 0.071 | 0.117 | 0.08 | T cell inhibitor | 0.08 0.067 DBMET01429 | DBMET01429 | |
| 0.073 | 0.119 | 0.344 | Cystathionine beta-synthase inhibitor | 0.122 0.056 DBMET03083 0.344 0.007 DBMET01429 | DBMET01429 | |
| 0.033 | 0.081 | 0.101 | Glucose-6-phosphate isomerase inhibitor | 0.101 0.005 DBMET03083 0.07 0.012 DBMET01429 | DBMET03083 | |
| 0.045 | 0.092 | 0.168 | Carbonic anhydrase VA inhibitor | 0.066 0.051 DBMET03083 0.168 0.008 DBMET01429 | DBMET01429 | |
| 0.012 | 0.061 | 0.077 | AMPA 3 receptor antagonist | 0.077 0.005 DBMET01429 | DBMET01429 | |
| 0.119 | 0.168 | 0.251 | 3C-like protease (Human coronavirus) inhibitor | 0.251 0.027 DBMET01429 | DBMET01429 | |
| 0.077 | 0.126 | 0.107 | Glutamate (mGluR7) agonist | 0.099 0.061 DBMET03083 0.107 0.047 DBMET01429 | DBMET01429 | |
| 0.017 | 0.066 | 0.054 | Integrin alpha2beta1 antagonist | 0.054 0.004 DBMET01429 | DBMET01429 | |
| 0.032 | 0.081 | 0.082 | Potassium channel (Inward rectifier) blocker | 0.082 0.012 DBMET03083 | DBMET03083 | |
| 0.017 | 0.067 | 0.105 | Purinergic P2Y14 antagonist | 0.105 0.004 DBMET01429 | DBMET01429 | |
| 0.022 | 0.072 | 0.052 | GHS receptor antagonist | 0.052 0.007 DBMET03083 | DBMET03083 | |
| 0.023 | 0.074 | 0.154 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.154 0.003 DBMET03083 | DBMET03083 | |
| 0.025 | 0.076 | 0.063 | Retinoid X receptor antagonist | 0.041 0.023 DBMET03083 0.063 0.005 DBMET01429 | DBMET01429 | |
| 0.154 | 0.205 | 0.241 | Transcription factor STAT3 inhibitor | 0.18 0.164 DBMET03083 0.241 0.09 DBMET01429 | DBMET01429 | |
| 0.037 | 0.089 | 0.078 | Heparanase inhibitor | 0.078 0.007 DBMET01429 | DBMET01429 | |
| 0.017 | 0.069 | 0.039 | Lysophosphatidic acid 2 receptor antagonist | 0.033 0.018 DBMET03083 0.039 0.013 DBMET01429 | DBMET01429 | |
| 0.024 | 0.076 | 0.055 | Angiotensin AT1 receptor antagonist | 0.055 0.011 DBMET01429 | DBMET01429 | |
| 0.021 | 0.074 | 0.044 | Angiotensin II receptor antagonist | 0.044 0.01 DBMET01429 | DBMET01429 | |
| 0.103 | 0.156 | 0.273 | Dual specificity phosphatase 3 inhibitor | 0.273 0.034 DBMET01429 | DBMET01429 | |
| 0.037 | 0.09 | 0.076 | Androgen agonist | 0.076 0.026 DBMET03083 0.058 0.043 DBMET01429 | DBMET03083 | |
| 0.004 | 0.058 | 0.038 | Glutamate (mGluR6) agonist | 0.038 0.003 DBMET01429 | DBMET01429 | |
| 0.004 | 0.058 | 0.018 | Angiotensin AT1B receptor antagonist | 0.018 0.007 DBMET01429 | DBMET01429 | |
| 0.015 | 0.069 | 0.029 | ICAM 1 antagonist | 0.029 0.007 DBMET03083 0.024 0.014 DBMET01429 | DBMET03083 | |
| 0.066 | 0.12 | 0.09 | Thioredoxin reductase inhibitor | 0.09 0.041 DBMET01429 | DBMET01429 | |
| 0.015 | 0.069 | 0.09 | Kainate receptor 2 antagonist | 0.09 0.005 DBMET01429 | DBMET01429 | |
| 0.09 | 0.145 | 0.115 | Activin receptor-like kinase 2 inhibitor | 0.115 0.103 DBMET03083 | DBMET03083 | |
| 0.024 | 0.079 | 0.056 | Ribonucleotide reductase inhibitor | 0.056 0.039 DBMET03083 0.051 0.042 DBMET01429 | DBMET03083 | |
| 0.029 | 0.084 | 0.071 | Adenylate cyclase 1 inhibitor | 0.071 0.012 DBMET03083 0.054 0.023 DBMET01429 | DBMET03083 | |
| 0.061 | 0.117 | 0.155 | Topoisomerase I inhibitor | 0.155 0.039 DBMET03083 | DBMET03083 | |
| 0.022 | 0.078 | 0.06 | Acetylcholine M1 receptor agonist | 0.06 0.022 DBMET03083 | DBMET03083 | |
| 0.024 | 0.081 | 0.036 | Protein kinase C beta I inhibitor | 0.036 0.015 DBMET01429 | DBMET01429 | |
| 0.024 | 0.08 | 0.053 | Ribonucleoside-diphosphate reductase inhibitor | 0.053 0.038 DBMET03083 0.05 0.041 DBMET01429 | DBMET03083 | |
| 0.031 | 0.087 | 0.054 | Toll-Like receptor 8 antagonist | 0.054 0.037 DBMET03083 | DBMET03083 | |
| 0.025 | 0.081 | 0.151 | NMDA receptor subunit 3B antagonist | 0.151 0.006 DBMET01429 | DBMET01429 | |
| 0.023 | 0.08 | 0.072 | Protein kinase (CK2) beta inhibitor | 0.032 0.027 DBMET03083 0.072 0.004 DBMET01429 | DBMET01429 | |
| 0.007 | 0.064 | 0.104 | AMPA 1 receptor antagonist | 0.104 0.005 DBMET01429 | DBMET01429 | |
| 0.021 | 0.078 | 0.081 | Carbonic anhydrase VII inhibitor | 0.081 0.013 DBMET01429 | DBMET01429 | |
| 0.04 | 0.097 | 0.111 | Fibroblast growth factor 2 antagonist | 0.111 0.02 DBMET03083 | DBMET03083 | |
| 0.013 | 0.07 | 0.038 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.038 0.003 DBMET03083 | DBMET03083 | |
| 0.006 | 0.064 | 0.049 | Retinoic acid receptor gamma antagonist | 0.049 0.003 DBMET01429 | DBMET01429 | |
| 0.038 | 0.096 | 0.087 | Factor III inhibitor | 0.087 0.006 DBMET01429 | DBMET01429 | |
| 0.055 | 0.113 | 0.092 | MDM2 inhibitor | 0.074 0.028 DBMET03083 0.092 0.01 DBMET01429 | DBMET01429 | |
| 0.015 | 0.073 | 0.06 | 5-Alpha-reductase inhibitor | 0.06 0.016 DBMET01429 | DBMET01429 | |
| 0.13 | 0.189 | 0.236 | Histone acetyltransferase inhibitor | 0.236 0.032 DBMET01429 | DBMET01429 | |
| 0.031 | 0.09 | 0.082 | Diacylglycerol O-acyltransferase inhibitor | 0.082 0.013 DBMET01429 | DBMET01429 | |
| 0.018 | 0.078 | 0.029 | Complement factor 1s inhibitor | 0.029 0.01 DBMET01429 | DBMET01429 | |
| 0.023 | 0.084 | 0.046 | Antimetabolite | 0.046 0.034 DBMET03083 0.046 0.034 DBMET01429 | DBMET01429 | |
| 0.026 | 0.089 | 0.109 | Dihydroorotase inhibitor | 0.109 0.005 DBMET01429 | DBMET01429 | |
| 0.005 | 0.069 | 0.013 | Purine nucleoside phosphorylase inhibitor | 0.013 0.007 DBMET03083 | DBMET03083 | |
| 0.033 | 0.097 | 0.068 | Phosphodiesterase VII inhibitor | 0.068 0.037 DBMET01429 | DBMET01429 | |
| 0.065 | 0.129 | 0.244 | Protein kinase (CK2) alpha inhibitor | 0.244 0.017 DBMET01429 | DBMET01429 | |
| 0.046 | 0.111 | 0.097 | Analgesic, opioid | 0.097 0.033 DBMET03083 | DBMET03083 | |
| 0.015 | 0.081 | 0.031 | Glutamate (mGluR2) antagonist | 0.031 0.019 DBMET01429 | DBMET01429 | |
| 0.034 | 0.1 | 0.056 | Phosphodiesterase 7A inhibitor | 0.056 0.028 DBMET01429 | DBMET01429 | |
| 0.025 | 0.091 | 0.037 | Calcium-independent phospholipase A2 inhibitor | 0.037 0.016 DBMET01429 | DBMET01429 | |
| 0.063 | 0.13 | 0.129 | Interleukin 5 antagonist | 0.129 0.018 DBMET03083 0.101 0.04 DBMET01429 | DBMET03083 | |
| 0.044 | 0.111 | 0.068 | Leukotriene C antagonist | 0.056 0.041 DBMET03083 0.068 0.016 DBMET01429 | DBMET01429 | |
| 0.016 | 0.083 | 0.038 | Retinoid X gamma receptor antagonist | 0.038 0.005 DBMET01429 | DBMET01429 | |
| 0.015 | 0.082 | 0.039 | Methionyl aminopeptidase 1 inhibitor | 0.039 0.013 DBMET01429 | DBMET01429 | |
| 0.041 | 0.109 | 0.069 | I kappa B kinase 2 inhibitor | 0.069 0.034 DBMET01429 | DBMET01429 | |
| 0.022 | 0.091 | 0.07 | Integrin alpha2 antagonist | 0.07 0.005 DBMET01429 | DBMET01429 | |
| 0.012 | 0.083 | 0.028 | Endothelial nitric-oxide synthase inhibitor | 0.028 0.026 DBMET03083 | DBMET03083 | |
| 0.068 | 0.139 | 0.175 | DNA polymerase I inhibitor | 0.095 0.091 DBMET03083 0.175 0.037 DBMET01429 | DBMET01429 | |
| 0.078 | 0.15 | 0.101 | CDK3/cyclin E inhibitor | 0.101 0.085 DBMET01429 | DBMET01429 | |
| 0.004 | 0.076 | 0.017 | Carbonic anhydrase XI inhibitor | 0.017 0.005 DBMET01429 | DBMET01429 | |
| 0.019 | 0.091 | 0.051 | Glutamate (mGluR group II) antagonist | 0.051 0.015 DBMET01429 | DBMET01429 | |
| 0.078 | 0.15 | 0.24 | M17 leucyl aminopeptidase inhibitor | 0.24 0.022 DBMET01429 | DBMET01429 | |
| 0.004 | 0.077 | 0.016 | Thrombopoietin agonist | 0.016 0.005 DBMET01429 | DBMET01429 | |
| 0.009 | 0.082 | 0.038 | Leukotriene B4 receptor 1 antagonist | 0.038 0.013 DBMET01429 | DBMET01429 | |
| 0.008 | 0.08 | 0.032 | Follicle-stimulating hormone agonist | 0.032 0.009 DBMET03083 | DBMET03083 | |
| 0.007 | 0.08 | 0.06 | Retinoic acid receptor antagonist | 0.06 0.004 DBMET01429 | DBMET01429 | |
| 0.078 | 0.151 | 0.115 | Factor V inhibitor | 0.115 0.044 DBMET01429 | DBMET01429 | |
| 0.011 | 0.085 | 0.023 | Isoleucine-tRNA ligase inhibitor | 0.023 0.014 DBMET03083 0.022 0.017 DBMET01429 | DBMET03083 | |
| 0.101 | 0.174 | 0.221 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.221 0.062 DBMET01429 | DBMET01429 | |
| 0.015 | 0.088 | 0.034 | Cholesterol ester transfer protein antagonist | 0.034 0.018 DBMET03083 | DBMET03083 | |
| 0.043 | 0.119 | 0.093 | Topoisomerase II alpha inhibitor | 0.093 0.044 DBMET03083 | DBMET03083 | |
| 0.014 | 0.09 | 0.137 | Nicotinic acid receptor agonist | 0.137 0.004 DBMET01429 | DBMET01429 | |
| 0.062 | 0.139 | 0.135 | Phosphodiesterase 7B inhibitor | 0.135 0.028 DBMET01429 | DBMET01429 | |
| 0.107 | 0.184 | 0.174 | CF transmembrane conductance regulator agonist | 0.129 0.121 DBMET03083 0.174 0.042 DBMET01429 | DBMET01429 | |
| 0.039 | 0.116 | 0.059 | 5 Hydroxytryptamine 3 agonist | 0.059 0.051 DBMET03083 | DBMET03083 | |
| 0.015 | 0.093 | 0.048 | Farnesoid X receptor agonist | 0.048 0.016 DBMET01429 | DBMET01429 | |
| 0.004 | 0.082 | 0.044 | Retinoic acid beta receptor antagonist | 0.044 0.003 DBMET01429 | DBMET01429 | |
| 0.032 | 0.111 | 0.054 | Bombesin 2 receptor antagonist | 0.054 0.028 DBMET03083 | DBMET03083 | |
| 0.002 | 0.081 | 0.007 | Insulin like growth factor 3 antagonist | 0.007 0.004 DBMET01429 | DBMET01429 | |
| 0.01 | 0.09 | 0.035 | Factor VII inhibitor | 0.035 0.017 DBMET01429 | DBMET01429 | |
| 0.009 | 0.09 | 0.104 | Kynurenine 3 monooxygenase inhibitor | 0.104 0.004 DBMET01429 | DBMET01429 | |
| 0.05 | 0.132 | 0.233 | Protein kinase (CK2) inhibitor | 0.233 0.013 DBMET01429 | DBMET01429 | |
| 0.107 | 0.188 | 0.148 | Antipruritic | 0.148 0.096 DBMET03083 0.144 0.102 DBMET01429 | DBMET03083 | |
| 0.027 | 0.109 | 0.072 | Kainate receptor agonist | 0.047 0.018 DBMET03083 0.072 0.004 DBMET01429 | DBMET01429 | |
| 0.12 | 0.202 | 0.177 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.177 0.098 DBMET03083 | DBMET03083 | |
| 0.1 | 0.182 | 0.375 | Aryl hydrocarbon receptor agonist | 0.375 0.042 DBMET01429 | DBMET01429 | |
| 0.007 | 0.09 | 0.019 | Telomerase stimulant | 0.019 0.009 DBMET03083 | DBMET03083 | |
| 0.019 | 0.102 | 0.05 | Dopamine D5 agonist | 0.046 0.021 DBMET03083 0.05 0.017 DBMET01429 | DBMET01429 | |
| 0.033 | 0.116 | 0.065 | Cyclin D1 inhibitor | 0.065 0.035 DBMET03083 0.063 0.038 DBMET01429 | DBMET03083 | |
| 0.013 | 0.097 | 0.026 | Thyroid hormone agonist | 0.026 0.018 DBMET03083 | DBMET03083 | |
| 0.161 | 0.245 | 0.227 | Caspase 3 stimulant | 0.227 0.135 DBMET03083 | DBMET03083 | |
| 0.027 | 0.112 | 0.045 | Leukotriene C4 antagonist | 0.045 0.015 DBMET01429 | DBMET01429 | |
| 0.004 | 0.089 | 0.062 | Kainate receptor 1 antagonist | 0.062 0.005 DBMET01429 | DBMET01429 | |
| 0.026 | 0.112 | 0.041 | Histamine H1 receptor agonist | 0.041 0.039 DBMET03083 | DBMET03083 | |
| 0.099 | 0.185 | 0.254 | Dual specificity phosphatase inhibitor | 0.254 0.037 DBMET01429 | DBMET01429 | |
| 0.005 | 0.091 | 0.02 | Aminopeptidase A inhibitor | 0.02 0.01 DBMET01429 | DBMET01429 | |
| 0.015 | 0.101 | 0.034 | Epoxide hydrolase 1 inhibitor | 0.034 0.017 DBMET01429 | DBMET01429 | |
| 0.048 | 0.135 | 0.093 | I kappa B kinase inhibitor | 0.093 0.045 DBMET01429 | DBMET01429 | |
| 0.033 | 0.121 | 0.057 | Botulinum neurotoxin type A inhibitor | 0.057 0.042 DBMET01429 | DBMET01429 | |
| 0.027 | 0.116 | 0.106 | Purinergic P2X2 antagonist | 0.106 0.027 DBMET01429 | DBMET01429 | |
| 0.037 | 0.126 | 0.08 | DNA gyrase inhibitor | 0.08 0.027 DBMET01429 | DBMET01429 | |
| 0.161 | 0.25 | 0.316 | Apoptosis antagonist | 0.316 0.075 DBMET01429 | DBMET01429 | |
| 0.007 | 0.097 | 0.078 | NMDA receptor glycine site antagonist | 0.078 0.004 DBMET01429 | DBMET01429 | |
| 0.004 | 0.094 | 0.011 | Integrin beta2 antagonist | 0.011 0.01 DBMET03083 | DBMET03083 | |
| 0.053 | 0.144 | 0.091 | Estrogen receptor alpha antagonist | 0.091 0.034 DBMET03083 | DBMET03083 | |
| 0.008 | 0.099 | 0.056 | Uridine phosphorylase inhibitor | 0.056 0.006 DBMET03083 0.047 0.009 DBMET01429 | DBMET03083 | |
| 0.099 | 0.191 | 0.18 | Melanin inhibitor | 0.18 0.051 DBMET03083 0.149 0.083 DBMET01429 | DBMET03083 | |
| 0.007 | 0.099 | 0.053 | Retinoic acid alpha receptor antagonist | 0.053 0.004 DBMET01429 | DBMET01429 | |
| 0.025 | 0.118 | 0.041 | Glucose-6-phosphate dehydrogenase inhibitor | 0.041 0.02 DBMET03083 | DBMET03083 | |
| 0.023 | 0.116 | 0.063 | Glutamate (mGluR8) antagonist | 0.063 0.005 DBMET01429 | DBMET01429 | |
| 0.091 | 0.185 | 0.133 | Cyclin-dependent kinase 8 inhibitor | 0.133 0.099 DBMET03083 0.13 0.103 DBMET01429 | DBMET03083 | |
| 0.037 | 0.131 | 0.078 | Fibroblast growth factor 3 antagonist | 0.078 0.054 DBMET03083 | DBMET03083 | |
| 0.148 | 0.242 | 0.27 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.27 0.088 DBMET03083 | DBMET03083 | |
| 0.08 | 0.175 | 0.14 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.14 0.096 DBMET03083 | DBMET03083 | |
| 0.059 | 0.154 | 0.1 | mTOR complex 2 inhibitor | 0.1 0.033 DBMET03083 0.086 0.054 DBMET01429 | DBMET03083 | |
| 0.027 | 0.122 | 0.049 | CC chemokine 2 receptor antagonist | 0.049 0.048 DBMET01429 | DBMET01429 | |
| 0.039 | 0.135 | 0.058 | Protease 3C (Human rhinovirus) inhibitor | 0.058 0.057 DBMET01429 | DBMET01429 | |
| 0.031 | 0.128 | 0.089 | Leukotriene antagonist | 0.089 0.027 DBMET01429 | DBMET01429 | |
| 0.153 | 0.251 | 0.364 | Immunosuppressant | 0.364 0.079 DBMET03083 0.26 0.14 DBMET01429 | DBMET03083 | |
| 0.041 | 0.138 | 0.064 | Epoxide hydrolase inhibitor | 0.064 0.063 DBMET01429 | DBMET01429 | |
| 0.089 | 0.188 | 0.172 | Farnesoid X receptor antagonist | 0.172 0.033 DBMET01429 | DBMET01429 | |
| 0.014 | 0.112 | 0.028 | Myristoyl transferase inhibitor | 0.028 0.016 DBMET03083 | DBMET03083 | |
| 0.002 | 0.102 | 0.007 | DNA topoisomerase III inhibitor | 0.007 0.006 DBMET01429 | DBMET01429 | |
| 0.004 | 0.104 | 0.013 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.013 0.009 DBMET03083 | DBMET03083 | |
| 0.018 | 0.119 | 0.053 | Potassium channel Kv1.3 blocker | 0.053 0.027 DBMET03083 | DBMET03083 | |
| 0.073 | 0.174 | 0.13 | Estrogen antagonist | 0.13 0.039 DBMET03083 | DBMET03083 | |
| 0.017 | 0.118 | 0.065 | Guanylate cyclase inhibitor | 0.061 0.011 DBMET03083 0.065 0.008 DBMET01429 | DBMET01429 | |
| 0.054 | 0.155 | 0.081 | Caspase 7 inhibitor | 0.081 0.06 DBMET03083 | DBMET03083 | |
| 0.082 | 0.187 | 0.154 | Sphingosine 1-phosphate receptor 4 antagonist | 0.118 0.076 DBMET03083 0.154 0.029 DBMET01429 | DBMET01429 | |
| 0.024 | 0.129 | 0.078 | CC chemokine 4 receptor antagonist | 0.078 0.007 DBMET03083 | DBMET03083 | |
| 0.013 | 0.119 | 0.044 | Factor VIIa inhibitor | 0.044 0.022 DBMET01429 | DBMET01429 | |
| 0.03 | 0.139 | 0.054 | CC chemokine receptor 2B antagonist | 0.054 0.026 DBMET03083 | DBMET03083 | |
| 0.187 | 0.296 | 0.282 | MAP kinase kinase 6 inhibitor | 0.282 0.154 DBMET01429 | DBMET01429 | |
| 0.026 | 0.135 | 0.07 | Protein kinase C eta inhibitor | 0.07 0.029 DBMET01429 | DBMET01429 | |
| 0.006 | 0.116 | 0.026 | Prostaglandin EP2 agonist | 0.026 0.014 DBMET01429 | DBMET01429 | |
| 0.007 | 0.117 | 0.016 | Kainate receptor 3 antagonist | 0.016 0.013 DBMET01429 | DBMET01429 | |
| 0.025 | 0.135 | 0.07 | Acetylcholine M5 receptor agonist | 0.07 0.044 DBMET03083 | DBMET03083 | |
| 0.048 | 0.159 | 0.085 | Antineoplastic alkaloid | 0.085 0.059 DBMET03083 | DBMET03083 | |
| 0.027 | 0.143 | 0.045 | CF transmembrane conductance regulator antagonist | 0.045 0.014 DBMET03083 0.039 0.029 DBMET01429 | DBMET03083 | |
| 0.063 | 0.179 | 0.119 | Caspase 3 inhibitor | 0.105 0.084 DBMET03083 0.119 0.062 DBMET01429 | DBMET01429 | |
| 0.069 | 0.185 | 0.136 | Folate antagonist | 0.136 0.028 DBMET01429 | DBMET01429 | |
| 0.019 | 0.139 | 0.049 | Tryptophan 5 hydroxylase inhibitor | 0.049 0.005 DBMET01429 | DBMET01429 | |
| 0.055 | 0.176 | 0.087 | Polo-like kinase-1 inhibitor | 0.087 0.068 DBMET03083 0.082 0.08 DBMET01429 | DBMET03083 | |
| 0.035 | 0.156 | 0.07 | Pregnane X receptor antagonist | 0.063 0.024 DBMET03083 0.07 0.014 DBMET01429 | DBMET01429 | |
| 0.103 | 0.225 | 0.154 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.154 0.122 DBMET03083 | DBMET03083 | |
| 0.034 | 0.157 | 0.093 | Cathepsin G inhibitor | 0.093 0.036 DBMET01429 | DBMET01429 | |
| 0.009 | 0.132 | 0.021 | Protease (Human cytomegalovirus) inhibitor | 0.021 0.017 DBMET01429 | DBMET01429 | |
| 0.06 | 0.184 | 0.212 | Bone formation stimulant | 0.212 0.033 DBMET03083 | DBMET03083 | |
| 0.044 | 0.168 | 0.084 | Peroxisome proliferator-activated receptor gamma antagonist | 0.084 0.028 DBMET01429 | DBMET01429 | |
| 0.016 | 0.141 | 0.066 | RNA-directed RNA polymerase inhibitor | 0.066 0.008 DBMET01429 | DBMET01429 | |
| 0.009 | 0.134 | 0.029 | Carnitine palmitoyltransferase 1A inhibitor | 0.029 0.019 DBMET01429 | DBMET01429 | |
| 0.008 | 0.135 | 0.055 | HCV NS5B polymerase inhibitor | 0.055 0.009 DBMET01429 | DBMET01429 | |
| 0.01 | 0.137 | 0.048 | Nicotinic acid receptor 2 antagonist | 0.048 0.004 DBMET01429 | DBMET01429 | |
| 0.006 | 0.134 | 0.051 | Somatostatin 5 antagonist | 0.051 0.013 DBMET01429 | DBMET01429 | |
| 0.018 | 0.146 | 0.098 | Dihydroorotate dehydrogenase inhibitor | 0.098 0.012 DBMET01429 | DBMET01429 | |
| 0.03 | 0.16 | 0.041 | Heme oxygenase inhibitor | 0.041 0.037 DBMET01429 | DBMET01429 | |
| 0.032 | 0.162 | 0.099 | Glucosylceramidase inhibitor | 0.099 0.008 DBMET03083 | DBMET03083 | |
| 0.007 | 0.138 | 0.042 | Glutamate (mGluR1a) agonist | 0.042 0.005 DBMET01429 | DBMET01429 | |
| 0.004 | 0.136 | 0.021 | Angiotensin AT1A receptor antagonist | 0.021 0.018 DBMET01429 | DBMET01429 | |
| 0.045 | 0.178 | 0.164 | Falcipain 3 inhibitor | 0.095 0.075 DBMET03083 0.164 0.03 DBMET01429 | DBMET01429 | |
| 0.114 | 0.248 | 0.258 | Hypoglycemic | 0.196 0.116 DBMET03083 0.258 0.072 DBMET01429 | DBMET01429 | |
| 0.006 | 0.14 | 0.041 | Kainate receptor 5 antagonist | 0.041 0.007 DBMET01429 | DBMET01429 | |
| 0.06 | 0.195 | 0.096 | CC chemokine 5 receptor agonist | 0.096 0.027 DBMET03083 | DBMET03083 | |
| 0.127 | 0.264 | 0.181 | MAP kinase kinase 5 inhibitor | 0.181 0.061 DBMET03083 | DBMET03083 | |
| 0.017 | 0.155 | 0.075 | Glutamate (mGluR4) agonist | 0.075 0.006 DBMET01429 | DBMET01429 | |
| 0.094 | 0.232 | 0.15 | MAP kinase 3 inhibitor | 0.15 0.068 DBMET03083 0.129 0.108 DBMET01429 | DBMET03083 | |
| 0.036 | 0.175 | 0.109 | Glutamate (mGluR7) antagonist | 0.109 0.007 DBMET01429 | DBMET01429 | |
| 0.009 | 0.15 | 0.028 | Prostaglandin F2 alpha agonist | 0.028 0.01 DBMET03083 | DBMET03083 | |
| 0.03 | 0.172 | 0.059 | Vanilloid 2 antagonist | 0.059 0.024 DBMET03083 | DBMET03083 | |
| 0.004 | 0.148 | 0.033 | Prostaglandin H2 antagonist | 0.033 0.01 DBMET01429 | DBMET01429 | |
| 0.024 | 0.169 | 0.073 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.073 0.02 DBMET03083 0.073 0.02 DBMET01429 | DBMET01429 | |
| 0.017 | 0.162 | 0.06 | Sphingosine 1-phosphate receptor agonist | 0.06 0.017 DBMET03083 0.04 0.038 DBMET01429 | DBMET03083 | |
| 0.008 | 0.154 | 0.053 | AMPA 2 receptor antagonist | 0.053 0.01 DBMET01429 | DBMET01429 | |
| 0.036 | 0.182 | 0.078 | CDC25A inhibitor | 0.078 0.046 DBMET01429 | DBMET01429 | |
| 0.113 | 0.259 | 0.235 | Lipoxygenase inhibitor | 0.235 0.11 DBMET01429 | DBMET01429 | |
| 0.004 | 0.153 | 0.014 | Thromboxane A2 agonist | 0.014 0.013 DBMET03083 | DBMET03083 | |
| 0.023 | 0.173 | 0.055 | DNA gyrase subunit A inhibitor | 0.055 0.013 DBMET01429 | DBMET01429 | |
| 0.021 | 0.172 | 0.059 | Selectin antagonist | 0.059 0.051 DBMET01429 | DBMET01429 | |
| 0.007 | 0.158 | 0.022 | Kainate receptor 4 antagonist | 0.022 0.021 DBMET01429 | DBMET01429 | |
| 0.04 | 0.192 | 0.137 | Urease inhibitor | 0.137 0.03 DBMET01429 | DBMET01429 | |
| 0.041 | 0.194 | 0.07 | Transcription factor RelA inhibitor | 0.07 0.03 DBMET01429 | DBMET01429 | |
| 0.02 | 0.173 | 0.135 | Glutamate (mGluR group III) agonist | 0.135 0.005 DBMET01429 | DBMET01429 | |
| 0.033 | 0.186 | 0.06 | Corticotropin releasing factor 2 receptor antagonist | 0.06 0.046 DBMET03083 | DBMET03083 | |
| 0.015 | 0.168 | 0.045 | Ceramide glucosyltransferase inhibitor | 0.045 0.01 DBMET03083 | DBMET03083 | |
| 0.004 | 0.157 | 0.021 | Prostaglandin E2 agonist | 0.021 0.019 DBMET01429 | DBMET01429 | |
| 0.028 | 0.182 | 0.088 | CDC25B inhibitor | 0.088 0.022 DBMET01429 | DBMET01429 | |
| 0.033 | 0.189 | 0.075 | Insulin growth factor antagonist | 0.075 0.074 DBMET03083 | DBMET03083 | |
| 0.066 | 0.224 | 0.277 | Mcl-1 antagonist | 0.277 0.028 DBMET01429 | DBMET01429 | |
| 0.016 | 0.174 | 0.028 | Hedgehog signaling activator | 0.028 0.017 DBMET03083 | DBMET03083 | |
| 0.023 | 0.183 | 0.058 | Guanylate cyclase stimulant | 0.058 0.015 DBMET01429 | DBMET01429 | |
| 0.007 | 0.168 | 0.03 | Prostaglandin agonist | 0.03 0.023 DBMET01429 | DBMET01429 | |
| 0.008 | 0.169 | 0.086 | Urate transporter 1 inhibitor | 0.086 0.007 DBMET01429 | DBMET01429 | |
| 0.025 | 0.188 | 0.067 | Sphingosine kinase 2 inhibitor | 0.067 0.024 DBMET03083 0.052 0.043 DBMET01429 | DBMET03083 | |
| 0.07 | 0.232 | 0.265 | Pyruvate kinase inhibitor | 0.265 0.057 DBMET01429 | DBMET01429 | |
| 0.01 | 0.173 | 0.055 | Urokinase inhibitor | 0.055 0.03 DBMET01429 | DBMET01429 | |
| 0.051 | 0.216 | 0.106 | Proteasome inhibitor | 0.106 0.079 DBMET03083 | DBMET03083 | |
| 0.017 | 0.184 | 0.055 | Fibroblast growth factor 4 antagonist | 0.055 0.044 DBMET03083 | DBMET03083 | |
| 0.039 | 0.207 | 0.08 | Phosphodiesterase VI inhibitor | 0.08 0.041 DBMET03083 | DBMET03083 | |
| 0.096 | 0.265 | 0.165 | MAP kinase kinase 4 inhibitor | 0.165 0.039 DBMET01429 | DBMET01429 | |
| 0.085 | 0.255 | 0.171 | Platelet antagonist | 0.171 0.125 DBMET03083 0.163 0.132 DBMET01429 | DBMET03083 | |
| 0.061 | 0.233 | 0.288 | Protein-tyrosine phosphatase inhibitor | 0.288 0.021 DBMET01429 | DBMET01429 | |
| 0.029 | 0.201 | 0.091 | Androgen antagonist | 0.091 0.053 DBMET03083 | DBMET03083 | |
| 0.053 | 0.226 | 0.164 | Thrombolytic | 0.164 0.072 DBMET01429 | DBMET01429 | |
| 0.034 | 0.207 | 0.126 | M18 aspartyl aminopeptidase inhibitor | 0.126 0.066 DBMET01429 | DBMET01429 | |
| 0.123 | 0.296 | 0.234 | Transcription factor STAT inhibitor | 0.234 0.098 DBMET01429 | DBMET01429 | |
| 0.04 | 0.213 | 0.075 | Sphingosine 1-phosphate receptor antagonist | 0.075 0.058 DBMET01429 | DBMET01429 | |
| 0.012 | 0.186 | 0.029 | Thymidine phosphorylase inhibitor | 0.029 0.013 DBMET03083 0.024 0.023 DBMET01429 | DBMET03083 | |
| 0.009 | 0.185 | 0.059 | Sphingosine 1-phosphate receptor 1 agonist | 0.059 0.013 DBMET03083 | DBMET03083 | |
| 0.011 | 0.187 | 0.034 | ATP citrate lysase inhibitor | 0.034 0.019 DBMET01429 | DBMET01429 | |
| 0.037 | 0.214 | 0.084 | Potassium channel activator | 0.084 0.069 DBMET01429 | DBMET01429 | |
| 0.063 | 0.24 | 0.121 | Histone deacetylase SIRT1 inhibitor | 0.121 0.09 DBMET01429 | DBMET01429 | |
| 0.007 | 0.186 | 0.032 | Free fatty acid receptor 1 antagonist | 0.032 0.026 DBMET01429 | DBMET01429 | |
| 0.075 | 0.257 | 0.138 | Sphingosine 1-phosphate receptor 2 agonist | 0.138 0.034 DBMET03083 | DBMET03083 | |
| 0.012 | 0.196 | 0.056 | Thromboxane A2 antagonist | 0.056 0.031 DBMET01429 | DBMET01429 | |
| 0.02 | 0.206 | 0.069 | Carnitine palmitoyltransferase 1B inhibitor | 0.069 0.012 DBMET01429 | DBMET01429 | |
| 0.043 | 0.229 | 0.105 | 5 Hydroxytryptamine 3A agonist | 0.105 0.07 DBMET01429 | DBMET01429 | |
| 0.004 | 0.191 | 0.039 | Nicotinic acid receptor 1 antagonist | 0.039 0.003 DBMET01429 | DBMET01429 | |
| 0.034 | 0.223 | 0.096 | Pim-1 kinase inhibitor | 0.096 0.062 DBMET01429 | DBMET01429 | |
| 0.04 | 0.231 | 0.085 | Aminoacyl-tRNA synthetase inhibitor | 0.081 0.075 DBMET03083 0.085 0.068 DBMET01429 | DBMET01429 | |
| 0.015 | 0.207 | 0.052 | Estrogen-related receptor beta antagonist | 0.052 0.005 DBMET03083 | DBMET03083 | |
| 0.117 | 0.311 | 0.294 | Immunomodulator | 0.294 0.086 DBMET03083 | DBMET03083 | |
| 0.014 | 0.209 | 0.058 | Thromboxane antagonist | 0.058 0.034 DBMET01429 | DBMET01429 | |
| 0.076 | 0.275 | 0.157 | Death-associated protein kinase 3 inhibitor | 0.157 0.111 DBMET01429 | DBMET01429 | |
| 0.018 | 0.217 | 0.104 | HIV-1 integrase (3'-Processing) inhibitor | 0.104 0.025 DBMET01429 | DBMET01429 | |
| 0.011 | 0.211 | 0.096 | Cannabinoid CB1 receptor agonist | 0.096 0.021 DBMET03083 | DBMET03083 | |
| 0.029 | 0.23 | 0.195 | Protein-tyrosine phosphatase 1B inhibitor | 0.195 0.031 DBMET01429 | DBMET01429 | |
| 0.025 | 0.226 | 0.052 | Sphingosine 1-phosphate receptor 1 antagonist | 0.052 0.049 DBMET03083 | DBMET03083 | |
| 0.022 | 0.226 | 0.071 | Sphingosine kinase inhibitor | 0.071 0.023 DBMET03083 0.055 0.05 DBMET01429 | DBMET03083 | |
| 0.009 | 0.216 | 0.124 | Nicotinic acid receptor 2 agonist | 0.124 0.005 DBMET01429 | DBMET01429 | |
| 0.015 | 0.222 | 0.037 | MAP3K5 inhibitor | 0.037 0.031 DBMET03083 | DBMET03083 | |
| 0.121 | 0.33 | 0.313 | Sodium/bile acid cotransporter inhibitor | 0.279 0.099 DBMET03083 0.313 0.068 DBMET01429 | DBMET01429 | |
| 0.02 | 0.231 | 0.061 | Leukotriene synthesis inhibitor | 0.061 0.054 DBMET01429 | DBMET01429 | |
| 0.036 | 0.246 | 0.118 | Glycogen synthase kinase-3 alpha inhibitor | 0.118 0.086 DBMET01429 | DBMET01429 | |
| 0.002 | 0.216 | 0.013 | Egl nine homolog 3 inhibitor | 0.013 0.007 DBMET01429 | DBMET01429 | |
| 0.056 | 0.276 | 0.168 | Interleukin 4 antagonist | 0.168 0.036 DBMET01429 | DBMET01429 | |
| 0.013 | 0.233 | 0.089 | HIV-1 integrase (Strand Transfer) inhibitor | 0.089 0.027 DBMET01429 | DBMET01429 | |
| 0.038 | 0.262 | 0.098 | Cell adhesion molecule inhibitor | 0.098 0.036 DBMET01429 | DBMET01429 | |
| 0.04 | 0.267 | 0.138 | Cyclooxygenase 1 inhibitor | 0.138 0.064 DBMET01429 | DBMET01429 | |
| 0.004 | 0.231 | 0.039 | Prostaglandin EP1 antagonist | 0.039 0.008 DBMET01429 | DBMET01429 | |
| 0.034 | 0.263 | 0.166 | Glutamate receptor antagonist | 0.166 0.041 DBMET01429 | DBMET01429 | |
| 0.052 | 0.282 | 0.132 | Cell adhesion inhibitor | 0.132 0.057 DBMET01429 | DBMET01429 | |
| 0.039 | 0.271 | 0.134 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.134 0.089 DBMET01429 | DBMET01429 | |
| 0.056 | 0.29 | 0.236 | Dyrk kinase inhibitor | 0.236 0.079 DBMET01429 | DBMET01429 | |
| 0.02 | 0.254 | 0.052 | Lysine-specific demethylase 1A inhibitor | 0.052 0.041 DBMET01429 | DBMET01429 | |
| 0.052 | 0.29 | 0.24 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.24 0.072 DBMET01429 | DBMET01429 | |
| 0.005 | 0.247 | 0.026 | Sodium/glucose cotransporter 2 inhibitor | 0.026 0.019 DBMET03083 | DBMET03083 | |
| 0.006 | 0.252 | 0.024 | Prostaglandin EP4 antagonist | 0.024 0.02 DBMET01429 | DBMET01429 | |
| 0.027 | 0.273 | 0.069 | Secretase beta inhibitor | 0.069 0.052 DBMET01429 | DBMET01429 | |
| 0.059 | 0.314 | 0.117 | Transcription factor STAT6 inhibitor | 0.117 0.066 DBMET01429 | DBMET01429 | |
| 0.059 | 0.315 | 0.215 | Hypolipemic | 0.215 0.085 DBMET03083 | DBMET03083 | |
| 0.018 | 0.279 | 0.036 | Vanilloid 3 antagonist | 0.036 0.034 DBMET03083 | DBMET03083 | |
| 0.013 | 0.274 | 0.104 | Plasminogen activator inhibitor antagonist | 0.104 0.009 DBMET01429 | DBMET01429 | |
| 0.005 | 0.268 | 0.042 | Factor XI inhibitor | 0.042 0.014 DBMET01429 | DBMET01429 | |
| 0.004 | 0.274 | 0.061 | Sphingosine 1-phosphate receptor 3 agonist | 0.061 0.011 DBMET03083 | DBMET03083 | |
| 0.015 | 0.285 | 0.038 | Acid-sensing ion channel blocker | 0.038 0.031 DBMET01429 | DBMET01429 | |
| 0.009 | 0.279 | 0.053 | Glutamate (mGluR group II) agonist | 0.053 0.014 DBMET01429 | DBMET01429 | |
| 0.006 | 0.28 | 0.045 | Glutamate (mGluR2) agonist | 0.045 0.016 DBMET01429 | DBMET01429 | |
| 0.033 | 0.309 | 0.155 | AMP-activated protein kinase stimulant | 0.155 0.025 DBMET01429 | DBMET01429 | |
| 0.036 | 0.313 | 0.085 | Vanilloid 4 agonist | 0.085 0.032 DBMET03083 | DBMET03083 | |
| 0.012 | 0.291 | 0.048 | Sphingosine kinase 1 inhibitor | 0.048 0.019 DBMET03083 | DBMET03083 | |
| 0.067 | 0.349 | 0.14 | Pregnane X receptor agonist | 0.14 0.072 DBMET03083 | DBMET03083 | |
| 0.009 | 0.3 | 0.058 | Factor XIa inhibitor | 0.058 0.013 DBMET01429 | DBMET01429 | |
| 0.012 | 0.306 | 0.131 | Glutamate receptor agonist | 0.131 0.023 DBMET01429 | DBMET01429 | |
| 0.042 | 0.341 | 0.119 | Anticoagulant | 0.119 0.114 DBMET01429 | DBMET01429 | |
| 0.006 | 0.308 | 0.024 | Sodium/glucose cotransporter inhibitor | 0.024 0.023 DBMET03083 | DBMET03083 | |
| 0.02 | 0.332 | 0.098 | Factor IXa inhibitor | 0.098 0.01 DBMET01429 | DBMET01429 | |
| 0.019 | 0.336 | 0.084 | Autotaxin inhibitor | 0.084 0.017 DBMET01429 | DBMET01429 | |
| 0.011 | 0.329 | 0.056 | Cyclin-dependent kinase 6 inhibitor | 0.056 0.046 DBMET03083 | DBMET03083 | |
| 0.008 | 0.342 | 0.059 | Cannabinoid receptor agonist | 0.059 0.049 DBMET03083 | DBMET03083 | |
| 0.026 | 0.364 | 0.068 | I kappa B kinase 1 inhibitor | 0.068 0.05 DBMET03083 | DBMET03083 | |
| 0.006 | 0.355 | 0.112 | Prostaglandin E2 antagonist | 0.112 0.013 DBMET01429 | DBMET01429 | |
| 0.052 | 0.402 | 0.127 | Polo-like kinase-3 inhibitor | 0.127 0.114 DBMET01429 | DBMET01429 | |
| 0.051 | 0.405 | 0.15 | Insulin secretagoues | 0.15 0.075 DBMET01429 | DBMET01429 | |
| 0.043 | 0.407 | 0.152 | Aurora-C kinase inhibitor | 0.152 0.048 DBMET03083 | DBMET03083 | |
| 0.012 | 0.383 | 0.061 | Nicotinic acid receptor 1 agonist | 0.061 0.016 DBMET01429 | DBMET01429 | |
| 0.015 | 0.424 | 0.081 | Prostaglandin F2 alpha antagonist | 0.081 0.021 DBMET01429 | DBMET01429 | |
| 0.005 | 0.422 | 0.066 | Prostaglandin EP2 antagonist | 0.066 0.036 DBMET01429 | DBMET01429 | |
| 0.019 | 0.446 | 0.047 | Antiviral (Hepatitis D) | 0.047 0.043 DBMET03083 | DBMET03083 | |
| 0.022 | 0.45 | 0.063 | DNA helicase inhibitor | 0.063 0.024 DBMET01429 | DBMET01429 | |
| 0.022 | 0.456 | 0.193 | Uric acid excretion stimulant | 0.193 0.014 DBMET01429 | DBMET01429 | |
| 0.005 | 0.448 | 0.055 | Prostaglandin antagonist | 0.055 0.035 DBMET01429 | DBMET01429 | |
| 0.043 | 0.521 | 0.138 | NOS3 expression enhancer | 0.138 0.086 DBMET01429 | DBMET01429 | |
| 0.049 | 0.688 | 0.26 | Antiinflammatory | 0.26 0.255 DBMET01429 | DBMET01429 | |
| 0.064 | 0.755 | 0.138 | CC chemokine 6 receptor antagonist | 0.138 0.044 DBMET01429 | DBMET01429 | |
| 0.023 | 0.775 | 0.299 | Cyclophilin D inhibitor | 0.299 0.164 DBMET01429 | DBMET01429 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |